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GENERAL INTRODUCTION
In the western world, the population is aging. People over 65 years are the fastest growing age 
group in the coming decades. Therefore, it is not surprising that several studies have indicated an 
increase in abdominal aortic aneurysms (AAAs) and consequently, ruptured AAAs (1-4).
An AAA is a weak area of the abdominal aorta that expands or bulges. This aneurysm is most 
likely caused by inflammation of the abdominal aorta that may lead to suspension of its wall. 
The AAA will enlarge by the pressure generated by each heartbeat, much like a balloon. Mostly, 
the AAA is not symptomatic until its rupture. Ruptured AAA is a life threatening condition that 
requires immediate intervention in order to avoid death.
In the Netherlands, the prevalence of AAAs among people over 55 years is 2.1%. The male:female 
ratio is 6:1 (5). Each year, about 800 people suffer from ruptured AAA (6).
The traditional approach to treat a ruptured AAA is open surgery. During open surgery, an inci-
sion is made in the abdomen to replace the ruptured part of the aorta with a tube-like aortic 
graft. Since 1994, endovascular repair in patients with a ruptured AAA has proven to be fea-
sible (7). During endovascular repair, incisions are made in the groin through which catheters are 
threaded to place an endovascular stent graft to treat the ruptured AAA. 
Mortality in patients with a ruptured AAA treated with open surgery remains high. Among 
patients who arrive in the hospital alive and undergo open surgery, the reported mortality rates 
varied between 32% and 70% and the morbidity rates between 30% and 50% (8, 9). Initial results 
of endovascular repair compared with open surgery were promising (10-22).  
Important advantages of endovascular repair are potential avoidance of general anesthesia and 
minimization of invasiveness, and blood loss is considerably less than with open surgery. Patients 
treated with endovascular repair, however, are expected to have complications in the long run 
due to graft failure, such as endoleak and graft migration (23-27). Patients treated with open 
surgery may have more severe complications during and immediately following the procedure, 
such as bleeding, cardiac and pulmonary complications, and ischemia of the sigmoid, whereas 
during follow-up complications are rare after open surgery.
Until now, no systematic evaluation of endovascular repair versus open surgery in patients with 
a ruptured AAA has been performed. In addition, it is not clear whether one treatment is superior 
in all patients. Endovascular repair may be a good option for some patients, whereas in other 
cases, open surgery may still be the best way to repair the ruptured AAA.
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APPROACH
Decisions in health care should be based on available evidence, the so-called evidence-based 
medicine approach. In a time when evidence from all over the world is available and accessi-
ble for physicians anywhere in the world, a systematic evaluation of the available evidence is 
needed. Furthermore, effects as well as costs should be taken into account when evaluating the 
best treatment option for patients. In addition, different people may require different treatment 
options and therefore, a prediction tool may be helpful in identifying those patients who would 
benefit from endovascular repair as opposed to open surgery. Since all available evidence needs 
to be used in a structured way, decision-analytic modeling should be incorporated in every 
decision-making process in health care.
AIM AND OUTLINE OF THIS THESIS
In this thesis, the approach described above was applied to patients with ruptured AAA. Our aim 
was to investigate whether endovascular repair or open surgery would be the preferred treat-
ment in this group of patients from a decision analytic approach, taking clinical effectiveness as 
well as costs into account. 
In chapter 2, we systematically evaluated published studies comparing endovascular repair with 
open surgery in patients with ruptured AAA and adjusted for differences in inclusion criteria 
among the studies. 
In chapter 3, we compared the clinical outcomes of treatment after endovascular repair and 
open surgery in patients with ruptured infrarenal AAAs including one-year follow-up.
The Glasgow Aneurysm Score (GAS) is a prediction rule recommended to predict in-hospital 
mortality after open surgery for patients with ruptured and unruptured AAA (28). In chapter 4, 
we validated the GAS in patients with ruptured AAA treated with endovascular repair or open 
surgery. In addition, we modified the GAS into an updated prediction rule that predicts 30-day 
mortality, taking into account the treatment modality, endovascular repair versus open surgery.
In chapter 5, we retrospectively assessed in-hospital costs and costs of 1-year follow-up of en-
dovascular aneurysm repair and conventional open surgery in patients with an acute infrarenal 
AAA, using the resource utilization approach.
In chapter 6, we evaluated the cost-effectiveness of endovascular repair compared with open 
surgery in patients with ruptured AAA and investigated whether it is worth to perform future 
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research to obtain additional information using value of information analysis techniques.
Finally, chapter 7 summarizes the main findings of the preceding chapters and discusses endo-
vascular repair versus open surgery in patients with ruptured AAA. In addition, methodological 
considerations and future research are discussed.
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ABSTRACT
Purpose: To perform a systematic review of studies that compared endovascular repair with 
open surgery in the treatment of patients with a ruptured abdominal aortic aneurysm (AAA). 
Materials and methods: A search of the English-language literature from January 1994 until 
March 2006 was performed. Inclusion criteria for articles were: patients who underwent endo-
vascular repair were compared to patients who underwent open surgery, each treatment group 
included at least 5 patients, information about patients’ hemodynamic condition upon presenta-
tion was reported, and (30-day) mortality was reported for each treatment group. Two reviewers 
independently extracted the data, and discrepancies were resolved by an arbiter. Random ef-
fects models and meta-regression analysis were used to calculate crude and adjusted odds ratios 
(endovascular versus open repair).
Results: Ten studies met the inclusion criteria in which the results of 478 procedures were 
reported (n = 148 for endovascular repair, n = 330 for open surgery). All studies were observa-
tional; no randomized controlled trials were found. The pooled 30-day mortality was 22% (95%-
confidence interval (CI) 16–29%) for endovascular repair and 38% (95%-CI 32–45%) for open 
surgery. The pooled total systemic complications were 28% (95%-CI 17–48%) for endovascular 
repair and 56% (95%-CI 37–85%) for open surgery. The crude odds ratio for the 30-day mortality 
for endovascular repair compared to open surgery was 0.45 (95%-CI 0.28–0.72). After adjustment 
for patients’ hemodynamic condition, the odds ratio was 0.67 (95%-CI 0.31–1.44). 
Conclusion: In our systematic review, after adjustment for patients’ hemodynamic condition 
upon presentation, a benefit in 30-day mortality for endovascular repair compared to open sur-
gery for patients with a ruptured AAA was observed but was not statistically significant. 
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INTRODUCTION
Open surgery has traditionally been the approach to treat abdominal aortic aneurysm (AAA) 
ruptures. Since 1994, endovascular repair has become available (1). Since then, this new 
technique has increasingly been used to treat ruptured AAAs (2). The initial results are very prom-
ising (3-5) and many hospitals have implemented the policy to treat patients with a ruptured 
AAA with endovascular repair provided the anatomy is suitable. Recently, however, published 
randomized trials comparing endovascular repair with open surgery in patients with an elec-
tive asymptomatic AAA concluded that there is only a short-term advantage of endovascular 
repair in these patients; (6, 7) in the long term (i.e., 4 years), they found that endovascular repair 
offers no survival advantage compared with open surgery (7). No randomized controlled trials 
comparing endovascular repair and open surgery in patients with a ruptured AAA have been 
published, to our knowledge. 
In several non-randomized studies mortality and morbidity data of endovascular repair were 
compared with conventional open surgery in patients with a ruptured AAA (8-17). The match-
ing criteria for endovascular repair and open surgery varied across the studies. As a result, these 
studies reported a wide range of estimates for short-term mortality and morbidity; for example, 
in patients with a ruptured AAA short-term mortality estimates for endovascular repair varied 
between 10% and 29% (10, 17), and for open surgery between 15% and 54% (12, 17). These 
studies were rather heterogeneous with respect to the inclusion of hemodynamically unstable 
patients in the open surgery group. To enable comparison of the results of endovascular repair 
with open surgery in patients with a ruptured AAA, it is important to systemically evaluate these 
published studies and to adjust for differences in inclusion criteria among the studies. Thus, the 
purpose of our study was to perform a systematic review of studies that compared endovascular 
repair with open surgery in the treatment of patients with a ruptured AAA. 
MATERIALS AND METHODS
To find the best available evidence, we formulated a PICO question (“the patient, population, or 
problem (P); the intervention or independent variable (I); the comparison (C); and the dependent 
variables or outcome(s) of interest (O)”) (18). The question was: “In patients with a ruptured AAA, 
would endovascular repair compared with open surgery lead to lower mortality and morbid-
ity?”
The literature was searched using the MEDLINE database and the Cochrane Library on literature 
reporting on endovascular repair and open surgery in patients with a ruptured AAA. The search 
was carried out on March 2, 2006 by one of the authors. We used keywords describing ruptured 
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abdominal aortic aneurysm, endovascular repair, open surgery, and outcome. Our search was 
limited to the English language and started from 1994 onward, when Yusuf published a case 
report on endovascular treatment of ruptured AAA in 1994 (1). To obtain additional references, 
articles that met our inclusion criteria were checked by one author by reviewing the reference 
list of each article. Furthermore, these articles were entered into the Web of Science database 
(19) in order to find where the articles that met our inclusion criteria were cited, so that related 
articles could be found. In addition, the computerized search strategy was validated by one au-
thor performing a manual search of the journals that reported most frequently about the topic 
of interest. These journals were searched from 1994 and included Radiology, Journal of Vascular 
and Interventional Radiology, Journal of Vascular Surgery, Journal of Endovascular Therapy, and 
European Journal of Vascular and Endovascular Surgery. Meeting abstracts, unpublished data, 
and theses were not included in our search. 
Prospective as well as retrospective studies were included if: (a) Patients who underwent endo-
vascular repair were compared to patients who underwent open surgery, (b) each treatment 
group included at least 5 patients, (c) information about patients’ hemodynamic condition upon 
presentation to the hospital was reported, (d) and (30-day) mortality was reported for each treat-
ment group. If studies reported results of current and historic controls separately, we included 
only the results of current controls. When multiple reports from one single institution were re-
trieved, the most recent report was included to avoid double counting. 
Two authors independently extracted data from each article using a standard form. Each of these 
two authors independently reviewed all articles. The arbiter considered discrepancies. The fol-
lowing data were recorded: (a) number of patients in each treatment group, (b) reasons to treat 
patients with open surgery, (c) patient characteristics, (d) AAA morphology, (e) whether a com-
puted tomography (CT)-scan was performed prior to the procedure, (f ) procedure characteristics 
such as type of anesthesia, type of graft, blood loss, procedure time, (g) mortality and morbidity 
rates during hospital stay, and (h) aneurysm-related complications during follow-up.
Data and Statistical Analysis
We assumed that the articles included in our systematic review were a random, unselective sam-
ple of a hypothetical population of studies comparing endovascular repair with open surgery 
in patients with a ruptured AAA. Therefore, to pool data, we used the random-effects model 
described by DerSimonian and Laird (20). This model took into account the between-study 
variability as well as the within-study variability. The pooled 30-day mortality with the 95%- 
confidence interval was calculated for both treatment groups. The total systemic complications 
were calculated as the sum of cardiac, pulmonary, cerebrovascular, and renal complications, mul-
tiorgan failure, and sepsis and were based on the studies that reported systemic complications 
for each treatment group (8, 11, 13, 15, 17). The pooled proportion of total systemic complica-
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tions with the 95%-confidence interval was calculated for each treatment group. Furthermore, 
we calculated the weighted means with the 95%-confidence interval for the mean age, mean 
AAA diameter, mean neck diameter, mean neck length, mean days in hospital, mean days in the 
intensive care unit (ICU), mean blood loss, mean blood transfusions, and mean time of the proce-
dure. The crude odds ratio for 30-day mortality with the 95%-confidence interval was calculated 
for endovascular repair versus open surgery (i.e., an odds ratio < 1.0 favored endovascular repair). 
Furthermore, an odds ratio for 30-day mortality adjusted for patients’ hemodynamic condition 
upon presentation in the hospital was calculated by performing a meta-regression analysis. In 
the regression model, we included the proportion of patients with low systolic blood pressures 
of each treatment group as covariate in the model.
Publication bias (i.e., bias resulting from the greater likelihood of publishing favorable results) 
was detected by a funnel plot (21). In the current study, we plotted the reciprocal of the standard 
error of the 30-day mortality odds ratio of each study as a function of the natural logarithm of the 
30-day mortality odds ratio. If no publication bias is present, the data points will be distributed 
in a symmetric fashion and shaped like an inverted V. Furthermore, to test for heterogeneity in 
patients’ hemodynamic condition upon presentation to the hospital across the studies, we used 
the χ2-test; p < 0.05 was considered statistically significant. Analyses were performed using Mi-
crosoft Excel 2000 (Microsoft Corporation, Redmond, WA) and SAS Version 8.2 (Statistical Analysis 
System, Cary, NC).
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RESULTS
Literature search
A total of 402 articles were identified from the MEDLINE database and Web of Science (Figure 1). 
 
Figure 1: Flowchart of the study selection procedure.
No additional articles were retrieved from the Cochrane Library, the review of the reference list 
of each article, and the manual search. Of these 402 articles, 56 papers were retrieved in full, of 
which 10 met our inclusion criteria (8-17). The total number of procedures was 478, 148 patients 
underwent endovascular repair and 330 patients underwent open surgery. Nine studies were 
performed in Europe and one in the United States (Table 1). 
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The articles were published between June 2003 and January 2006; patients were enrolled from 
1996 to 2004. All studies were observational and single-center; no randomized controlled trials 
were found. The size of the treatment groups varied between 6 and 25 for endovascular repair 
and between 10 and 172 for open surgery. Two studies did not report results for current and his-
toric controls separately for patients treated with open surgery, therefore we used the combined 
results (8, 14). 
Patient selection
Across the studies, the treatment choice for endovascular repair or open surgery in patients with 
a ruptured AAA varied (Table 2).  
Table 2: Reasons to treat patients with a ruptured Abdominal Aortic Aneurysm (AAA) with 
open surgery instead of endovascular repair 
CI = confidence interval, NR = not reported
* The definition for hemodynamic instability differed across the selected studies.
† Anatomic considerations were: inaccessible iliac arteries, too short infrarenal neck, sharply angled infrarenal neck, diameter infra-
renal neck too large, calcified neck, or mycotic aneurysm.
‡ Unavailability of endovascular equipment or trained staff.
§ Not reported separately for patients with a ruptured AAA (n = 10) and patients with a symptomatic AAA (n = 4).
|| Not reported separately for patients with a ruptured AAA and patients with a symptomatic AAA and only reported for patients 
treated between January 2003 and August 2004 (15 patients underwent endovascular repair and 41 underwent open surgery).
# In 6/17 patients endovascular repair was not considered at all by the surgeon.
** Six of these 9 patients underwent open surgery at discretion of the attending surgeon. 
†† We assumed that all patients who were too unstable to tolerate a CT-scan prior to the procedure and transported immediately 
to the operating theatre for open surgery, were patients with a ruptured AAA. 
Study
Number of  
patients treated 
with open surgery
Hemodynamic 
instability 
(%)*
Anatomic 
considerations 
(%)†
Logistic 
reasons 
(%)‡
Peppelenbosch et al (8)§ 14 3/14 (21) 5/14 (36) 6/14 (43)
Reichart et al (9) 17 3/17 (18) 12/17 (71) 2/17 (12)
Resch et al (10) 23 2/23 (9) 3/23 (13) 18/23 (78)
Alsac et al (11) 20 8/20 (40) 7/20 (35) 5/20 (25)
Brandt et al (12) 13 0/13 (0) 11/13 (85) 2/13 (15)
Castelli et al (13) 21 0/21 (0) 18/21 (86) 3/21 (14)
Kapma et al (14)|| 172 8/41 (20) 29/41 (71) 4/41 (10)
Larzon et al (15) 26 5/26 (19) 4/26 (15) 17/26 (65)#
Vaddineni et al (16) 15 6/15 (40) 9/15 (60)** 0/15 (0)
Franks et al (17) 13 6/13 (46)†† NR NR
Pooled outcome (95%-CI) - 0.24 (0.17-0.34) 0.52 (0.32-0.71) 0.28 (0.14-0.49)
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In general, the policy of the hospitals in the selected studies was to preferentially treat patients 
with endovascular repair. Patients who were stable enough (i.e., no hypovolemic shock or cardiac 
arrest) underwent CT-scan prior to the procedure. If the AAA was anatomically suitable and the 
required endovascular equipment and trained staff were available, the patient was treated with 
endovascular repair. In some studies the majority of patients were treated with open surgery in-
stead of endovascular repair because of anatomic considerations (12, 13), whereas in other stud-
ies open surgery instead of endovascular repair was performed because of logistic reasons such 
as unavailability of endovascular equipment or trained staff (Table 2) (10, 15). Across the studies, 
the majority of the patients were male and this proportion was similar between the endovascular 
repair and the open surgery group (p = 0.74). Mean age was similar for the endovascular repair 
and the open surgery group. The hemodynamic condition of patients upon presentation to the 
hospital varied between the studies for both endovascular repair and open surgery (Table 3). 
Procedure characteristics
In 7 of 10 studies, all patients treated with endovascular repair had a CT-scan prior to the proce-
dure, whereas the proportion of patients treated with open surgery that underwent a CT-scan 
prior to the procedure varied between 43% and 74% across the studies (Table 4).
In some studies, the use of regional and/or epidural anesthesia was preferred for patients treated 
with endovascular repair (8, 9, 14), whereas in the other studies general anesthesia was preferred 
for those patients. In studies that reported on the type of anesthesia in patients treated with 
open surgery, general anesthesia was mostly used in those patients. In some studies, the major-
ity of patients treated with endovascular repair received an aorto-uni-iliac graft (8-10, 12), where-
as in other studies the majority of patients treated with endovascular repair received a bifurcated 
graft (13-17). In studies that reported on the type of grafts used in patients treated with open 
surgery, most patients received a tubular graft. 
Outcomes
In studies that reported intraoperative mortality for the endovascular repair and the open sur-
gery group, the intraoperative mortality was lower for patients treated with endovascular repair 
(Table 5).
In addition, all studies showed lower 30-day mortality rates for patients treated with endovascu-
lar repair compared to those patients who underwent open surgery. The pooled 30-day mortality 
was 22% (95%-confidence interval 16–29%) for endovascular repair and 38% (95%-confidence 
interval 32–45%) for open surgery. The crude odds ratio for 30-day mortality of endovascular 
repair versus open surgery was 0.45 (95%-confidence interval 0.28–0.72). Heterogeneity was 
demonstrated for the patients’ hemodynamic condition upon presentation to the hospital across 
the studies for both treatment groups (p < 0.01). After adjustment for patients’ hemodynamic 
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Table 3: Patient characteristics and Abdominal Aortic Aneurysm (AAA) morphology of 
patients with a ruptured AAA treated with endovascular repair or open surgery
mm = millimeter, NR = not reported, CI = confidence interval
* Circulatory shock was defined by Peppelenbosch et al and by Franks et al for endovascular patients as systolic blood pressure 
< 100 millimeter Mercury (mm Hg), by Reichart et al, Castelli et al, Larzon et al, and Vaddineni et al as systolic blood pressure 
< 80 mm Hg, by Resch et al as syncope before procedure, by Alsac et al as systolic blood pressure < 60 mm Hg, by Brandt et al as 
preoperative hypotension, by Kapma et al as systolic blood pressure < 70 mm Hg for patients undergoing endovascular repair and 
as too shocked to undergo a CT-scan prior to the procedure for patients undergoing open surgery, and by Franks et al as patients 
transported directly to the operating theatre for patients under-going open surgery.
† Patient characteristics were not reported separately for patients with a ruptured AAA and patients with a symptomatic AAA; 
Peppelenbosch: total number of patients treated with endovascular repair = 26, total number of patients treated with open surgery 
= 14; Kapma: total number of patients treated with endovascular repair = 40, total number of patients treated with open surgery 
= 213; Franks: total number of patients treated with endovascular repair = 21, total number of patients treated with open surgery 
= 22.
‡ We assumed that all patients with systolic blood pressure < 100 mm Hg were patients with a ruptured AAA.
§ Patient characteristics were not reported separately for endovascular and open treated patients; Reichart: total number of 
patients treated with endovascular repair = 6, total number of patients treated with open surgery = 18; Brandt: total number of 
patients treated with endovascular repair = 11, total number of patients treated with open surgery = 13.
|| One patient with a symptomatic AAA was included who underwent open surgery.
# We assumed that all patients with preoperative hypotension were treated with open surgery since Brandt et al stated that 
patients who were in hemodynamically unstable condition went directly to the operating room and underwent open surgery.
** Median.
†† Only reported for patients who underwent a CT-scan prior to the procedure; one patient was treated for a symptomatic AAA.
‡‡ Only reported for 41 patients treated with open surgery between January 2003 and August 2004.
§§ We assumed that all patients who were transported immediately to the operating theatre were patients with a ruptured AAA. 
Study Number 
of patients
Ruptured - 
Symptomatic
Male 
(%)
Mean age 
(yr)
Circulatory 
shock (%)*
Mean AAA 
diameter
(mm)
Mean neck 
diameter 
(mm)
Mean neck 
length
(mm)
Endovascular repair
Peppelenbosch et al (8) 16 16-10 23/26 (88)† 74.1† 8/16 (50)‡ 67† 23.8† 18.0†
Reichart et al (9) 6 - 23/26 (88) §, || 71§, || 0/6 (0) 64 NR 23
Resch et al (10) 14 - 11/14 (79) 79 5/14 (36) 60 NR NR
Alsac et al (11) 17 - 16/17 (94) 72.9 0/17 (0) 85 22.1 27.4
Brandt et al (12) 11 - 19/24 (79) § 75§ 0/11 (0) # 71 NR NR
Castelli et al (13)† 25 - 21/25 (84) 76 7/25 (28) 73 NR NR
Kapma et al (14) 25 25-15 37/40 (93)† 75†, ** 7/25 (28) NR NR NR
Larzon et al (15) 15 - 14/15 (93) 73** 11/15 (73) NR NR NR
Vaddineni et al (16) 9 - 7/9 (78) 70.8 0/9 (0) 67 NR NR
Franks et al (17) 10 10-11 19/21 (90)† 73.7† 3/10 (30) NR NR NR
Pooled outcome 
(95%-CI)
- -
0.85 
(0.80-0.89)
74.2 
(70.3-78.1)
0.29
 (0.17-0.46)
71 
(56-85)
23 
(21-25)
22 
(13-31)
Open surgery
Peppelenbosch et al (8) 10 10-4 11/14 (79)† 71.0† 8/10 (80)‡ 77 27.8 7.5
Reichart et al (9) 17 17-1 23/26 (88) §, || 71§, || 3/17 (18) 88†† NR NR
Resch et al (10) 23 - 20/23 (87) 73 17/23 (74) 70 NR NR
Alsac et al (11) 20 - 20/20 (100) 72.8 8/20 (40) 78.8 21.2 13.5
Brandt et al (12) 13 - 19/24 (79) § 75§ 4/13 (31) # 77 NR NR
Castelli et al (13) 21 - 17/21 (81) NR 8/21 (38) NR NR NR
Kapma et al (14) 172 172-41 185/213 (87)† 71†, ** 8/41 (20) ‡‡ NR NR NR
Larzon et al (15) 26 - 23/26 (88) 75** 10/26 (38) NR NR NR
Vaddineni et al (16) 15 - 12/15 (80) 72.2 6/15 (40) 64 NR NR
Franks et al (17) 13 13-9 20/22 (91)† 71.8† 6/13 (46) §§ NR NR NR
Pooled outcome 
(95%-CI)
- - 0.85 
(0.81-0.88)
71.8 
(69.1-74.5)
0.41 
(0.30-0.54)
75 
(61-89)
24 
(18-31)
11 
(5.2-17)
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Table 4: Procedure characteristics of patients with a ruptured Abdominal Aortic Aneurysm 
treated with endovascular repair or open surgery 
AAA = Abdominal Aortic Aneurysm, CT = computed tomography, AUI = aorto-uni-iliac, NR = not reported
* Peppelenbosch: Three patients underwent fluoroscopic assessment in the operating room to establish neck diameter and neck 
length. Resch: One patient with a known AAA had a rupture in-hospital; one patient had intraoperative CO2 angiography to verify 
the AAA rupture.
† Procedure characteristics were not reported separately for patients treated with endovascular repair with a ruptured AAA and with a 
symptomatic AAA; Peppelenbosch: 16 patients with a ruptured AAA, 10 patients with a symptomatic AAA; Kapma: 25 patients with a 
ruptured AAA, 15 patients with a symptomatic AAA; Franks: 10 patients with a ruptured AAA, 11 patients with a symptomatic AAA.
‡ Regional or local anesthesia.
§ Only reported for 21 patients with a ruptured AAA who underwent endovascular repair between 1997 and July 2002.
|| Iliac extension.
# Only reported for 15 patients with a ruptured AAA treated with endovascular repair between January 2003 and August 2004.
**  Among patients treated with endovascular repair, 2/15 received combinations of different stent-grafts.
†† Four patients received general anesthesia only, 3 patients received local anesthesia with sedation.
‡‡ Procedure characteristics were not reported separately for patients treated with open surgery with a ruptured AAA and with a 
symptomatic AAA; Peppelenbosch: 10 patients with a ruptured AAA, 4 patients with a symptomatic AAA; Kapma: only reported for 
patients treated between January 2003 and August 2004, not reported how many patients had ruptured AAA or symptomatic AAA 
in this period. 
Study CT-scan prior 
to procedure 
(%)
Local 
anesthesia 
(%)
General 
anesthesia 
(%)
AUI-graft (%) Bifurcated 
graft (%)
Tubular 
graft (%)
Endovascular repair
Peppelenbosch et al (8) 23/26 (88)*, † 15/16 (94)‡ 1/16 (6) 19/26 (73)† 3/16 (19)† 2/26 (8)†
Reichart et al (9) 6/6 (100) 4/6 (67) 2/6 (33) 6/6 (100) 0/6 (0) 0/6 (0)
Resch et al (10) 12/14 (86)* 6/21 (29)§ 15/21 (79)§ 12/21 (57)§ 9/21 (43)§ 0/21 (0)
Alsac et al (11) 17/17 (100) 1/17 (6) 16/17 (94) 8/17 (47) 8/17 (47) 1/17 (6)||
Brandt et al (12) 11/11 (100) 0/11 (0) 11/11 (100) 8/11 (73) 3/11 (27) 0/11 (0)
Castelli et al (13)† 23/25 (92) 0/25 (0) 25/25 (100) 4/25 (16) 21/25 (84) 0/25 (0)
Kapma et al (14) 15/15 (100)# 33/40 (83)† 7/40 (17)†,†† 1/40 (3)† 39/40 (97)† 0/40 (0)†
Larzon et al (15) 15/15 (100) 2/15 (13) 13/15 (87) NR 13/15 (87)** NR
Vaddineni et al (16) 9/9 (100) 0/9 (0) 9/9 (100) 0/9 (0) 9/9 (100) 0/9 (0)
Franks et al (17) 10/10 (100) 7/21 (33)†,** 14/21 (67)† 4/21 (19)† 17/21 (81)† 0/21 (0)†
Pooled outcome (95%-CI) 0.91 (0.85-0.95) 0.29 (0.11-0.58) 0.71 (0.42-0.89) 0.38 (0.17-0.64) 0.64 (0.38-0.83) 0.05 (0.03-0.10)
Open surgery
Peppelenbosch et al (8) 10/14 (71)‡‡ 0/10 (0) 10/10 (100) 0/14 (0)‡‡ 5/14 (29)‡‡ 9/14 (64)‡‡
Reichart et al (9) 12/17 (71) NR NR 0/17 (0) 5/17 (29) 12/17 (71)
Resch et al (10) 17/23 (74) 0/23 (0) 23/23 (100) 0/23 (0) 7/23 (30) 16/23 (70)
Alsac et al (11) 12/20 (60) 0/20 (0) 20/20 (100) 0/20 (0) 10/20 (50) 10/20 (50)
Brandt et al (12) NR NR NR 0/13 (0) NR NR
Castelli et al (13) 9/21 (43) 0/21 (0) 21/21 (100) NR NR NR
Kapma et al (14) 26/41 (63)‡‡ NR NR NR NR NR
Larzon et al (15) 15/26 (58) 1/26 (4) 25/26 (96) 0/26 (0) 4/26 (15) 22/26 (85)
Vaddineni et al (16) 9/15 (60) 0/15 (0) 15/15 (100) NR NR NR
Franks et al (17) 7/13 (54) NR NR NR NR NR
Pooled outcome (95%-CI) 0.61 (0.54-0.67) 0.04 (0.01-0.09) 0.96 (0.91-0.99) 0.03 (0.01-0.08) 0.33 (0.22-0.45) 0.67 (0.55-0.78)
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Table 5: Outcomes in patients with a ruptured Abdominal Aortic Aneurysm treated with 
endovascular repair or open surgery 
AAA = Abdominal Aortic Aneurysm, ICU = intensive care unit, ml = milliliter, NR = not reported, p.c. = units of packed cells, CI = confidence 
interval
* Outcomes were not reported separately for patients treated with endovascular repair with a ruptured AAA and with a symptomatic 
AAA; Peppelenbosch: 16 patients with a ruptured AAA, 10 patients with a symptomatic AAA; Kapma: 25 patients with a ruptured AAA, 15 
patients with a symptomatic AAA; Franks: 10 patients with a ruptured AAA, 11 patients with a symptomatic AAA.
† Not stated if mean or median was reported.
‡ Median.
§ In-hospital mortality.
|| Not stated whether 30-day or in-hospital mortality was reported.
# Weighted mean.
** Outcomes were not reported separately for open treated patients with a ruptured AAA and with a symptomatic AAA; Peppelenbosch: 
10 patients with a ruptured AAA, 4 patients with a symptomatic AAA; Kapma: 172 patients with a ruptured AAA, 41 patients with a symp-
tomatic AAA; Franks: 13 patients with a ruptured AAA, 9 patients with a symptomatic AAA.
†† Total in-hospital mortality was 7/17, 4/12 patients who underwent a computed tomography (CT)-scan died in-hospital, 3/5 patients who 
did not undergo a CT-scan died in-hospital.
‡‡ Only reported for 13 patients who underwent a CT-scan prior to procedure. One patient underwent open surgery for symptomatic 
AAA. 
Study Intraoperative
mortality 
(%)
30-day 
mortality 
(%)
Mean days 
in hospital
Mean 
days in 
the ICU
 Mean blood
 loss in ml
Mean blood 
transfusions
Mean 
procedure
time (minutes)
Endovascular 
repair
Peppelenbosch 
et al (8)
NR 4/16 (25) 7.2*,† 1.9*, † 1100* 4700 ml* 154*
Reichart et al (9) 0/6 (0) 1/6 (17) 8 2.25 300 0 ml 163
Resch et al (10) NR 4/14 (29) NR 1‡ 800† 2 units† NR
Alsac et al (11) NR 4/17 (24) 11.5‡ 3‡ NR 1520 ml 156
Brandt et al (12) NR 0/11 (0)§ 13.9 4.8 NR 964 ml 178
Castelli et al (13)† NR 5/25 (20)|| 7 4.7 243 NR 115
Kapma et al (14) 1/25 (4) 5/25 (20) 5*,‡ 0*,‡ 200*,‡ 0 p.c.*,‡ 110*,‡
Larzon et al (15) 0/15 (0) 2/15 (13) NR NR NR NR NR
Vaddineni 
et al (16)
0/9 (0) 2/9 (22) 19.5 13 475 3.78 units 143
Franks et al (17) 0/10 (0) 1/10 (10) 8.5* 1.5* NR 0.86 units* 156*
Pooled outcome 
(95%-CI)
0.05 (0.02-0.14) 0.22 (0.16–0.29) 8.5# (1.2-16) 2.6# (0-8.5) 500# (0-1218 1255# (0-4571) 138#  (92-184)
Open surgery
Peppelenbosch 
et al (8)
NR 4/10 (40) 22.1†, ** 6.4†, ** 2600** 10400 ml** 155**
Reichart et al (9) NR 7/17 (41)†† 29‡‡ 13‡‡ 4500‡‡ 1600 ml‡‡ 132‡‡
Resch et al (10) NR 8/23 (35) NR 3‡ 4000† 9 units† NR
Alsac et al (11) NR 10/20 (50) 20‡ 13‡ NR 3075 ml 222
Brandt et al (12) NR 2/13 (15)§ 19.1 8.5 NR 1968 ml 207
Castelli et al (13) NR 10/21 (48)|| NR NR NR NR NR
Kapma et al (14) NR 57/172 (33)§ 12‡,** 2‡,** 3500‡,** 6 p.c.‡, ** 180‡,**
Larzon et al (15) 6/26 (23) 12/26 (46) NR NR NR NR NR
Vaddineni 
et al (16)
3/15 (20) 4/15 (27) 27 19.5 2880 6.93 units 181
Franks et al (17) NR 7/13 (54) 17.5** 6.1** NR 10.7 units** 186**
Pooled outcome
 (95%-CI)
0.23 (0.13-0.38) 0.38 (0.32–0.45) 15#  (5.0-25) 4.7#  (0-14) 3509# (2806-4213) 2268# (0-5732) 181#  (149-213)
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condition upon presentation to the hospital, the odds ratio was 0.67 (95%-confidence interval 
0.31–1.44; p = 0.37) indicating that the difference in 30-day mortality was, in part, explained by 
this variable (Figure 2).
The mean number of days spent in hospital (8.5 versus 15 days for endovascular repair and 
open surgery, respectively) and in the ICU (2.6 versus 4.7 days for endovascular repair and open 
surgery, respectively) was less after endovascular repair than after open surgery (Table 5). In 
addition, studies that reported blood loss and blood transfusions during the procedure showed 
less blood loss and less blood transfusions following endovascular repair than following open 
surgery. The duration of an endovascular procedure was shorter in most studies compared to 
an open surgical procedure (138 versus 181 minutes for endovascular repair and open surgery, 
respectively).
Five studies reported complications for both endovascular repair and open surgery (Table 6) (8, 
11, 13, 15, 17).  
Figure 2: Forest plot representation on 30-day mortality as reported in included studies.
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Table 6: In-hospital complications in patients with a ruptured Abdominal Aortic Aneurysm 
treated with endovascular repair or open surgery
AAA = Abdominal Aortic Aneurysm, NR = not reported, CI = confidence interval
* Reported in studies as cardiac complications, myocardial infarction, (cardiac) arrhythmia, angina, and congestive cardiac failure.
† Reported in studies as pulmonary complications, pneumopathy, pulmonary embolism, respiratory complications, respiratory tract 
infection, and respiratory failure.
‡ Reported in studies as cerebrovascular accident, stroke, and cerebrovascular complications. 
§ Reported in studies as (acute) renal failure, renal complications, and renal impairment. 
|| Reported in studies as wound infection, hematoma, and deep infection.
# Complications were not reported separately for patients with a ruptured AAA (n = 16) and patients with a symptomatic AAA (n = 10).
** In addition, Alsac et al reported that among patients treated with endovascular repair, 1/17 patients had visceral ischemia and 1/17 
patients had limb ischemia.  
†† In addition, Castelli et al reported that among patients treated with endovascular repair, 3/25 patients had post-implant syndrome.
‡‡ Two of 25 patients had type 1 endoleaks, 1/25 patients had type 3 endoleak.
§§ In addition, Larzon et al reported that among patients treated with endovascular repair, 4/15 patients had thrombo-embolic complica-
tions.
|||| In addition, Franks et al reported that among patients treated with endovascular repair, 1/21 patients had colon ischemia and 2/21 
patients had groin seromas. Complications were not reported separately for patients with a ruptured AAA (n = 10) and patients with a 
symptomatic AAA (n = 11).
## Type 1 endoleak.
*** Complications were not reported separately for patients with a ruptured AAA (n = 10) and patients with a symptomatic AAA (n = 4).
††† In addition, Alsac et al reported that among patients treated with open surgery, 3/20 patients had visceral ischemia and 1/20 patients 
had limb ischemia.
‡‡‡ In addition, Castelli et al reported that among patients treated with open surgery, 3/21 patients had disseminated intravascular 
coagulopathy, 1/21 patients had colon ischemia, 1/21 patients had aortic thrombosis, and 1/21 patients had gangrene.
§§§ In addition, Larzon et al reported that among patients treated with open surgery, 5/26 patients had thrombo-embolic complica-
tions.
|||||| In addition, Franks et al reported that among patients treated with open surgery, 4/22 patients had colon ischemia, 1/22 patients 
had gastro-intestinal bleeding, and 1/22 patients had common femoral artery embolus. Complications were not reported separately for 
patients with a ruptured AAA (n = 13) and patients with a symptomatic AAA (n = 9). 
Study Cardiac*  
(%)
Pulmo-
nary† 
(%)
Cerebro-
vascular‡ 
(%)
Renal§
(%) 
Multiorgan 
failure or 
sepsis (%)
Endoleak 
(%)
Graft 
infection 
(%)
Wound 
infection||
(%)
Abdominal 
compartment 
syndrome (%)
Endovascular 
repair
Peppelenbosch
et al (8)
2/26 (8)# 1/26 (4)# 1/26 (4)# NR 0/16 (0) NR NR 4/26 (15)# NR
Alsac et al (11)** 0/17 (0) 1/17 (6) 2/17 (12) 2/17 (12) 1/17 (6) NR 0/17 (0) NR 1/17 (6)
Castelli et al (13)†† 0/25 (0) 0/25 (0) NR 2/25 (8) NR 3/25 (12)‡‡ NR 2/25 (8) 1/25 (4)
Larzon et al (15)§§ 2/15 (13) 0/15 (0) 2/15 (13) 2/15 (13) 2/15 (13) NR NR 0/15 (0) 1/15 (7)
Franks et al (17)|||| 2/21 (10) 2/21 (10) NR 2/21 (10) NR 4/21 (19)## NR 1/21 (5) NR
Pooled outcome 
(95%-CI)
0.10
(0.05-0.18)
0.07
(0.03-0.14)
0.12
(0.05-0.23)
0.12 
(0.07-0.22)
0.10
(0.04-0.24)
0.17
(0.09-0.30)
-
0.11
(0.06-0.20)
0.08
(0.03-0.18)
Open surgery
Peppelenbosch 
et al (8)
0/10 (0) 2/14 (14) *** 0/10 (0) NR 1/14 (7)*** - NR 0/10 (0) NR
Alsac et al (11)††† 2/20 (10) 5/20 (25) 2/20 (10) 4/20 (20) 2/20 (10) - 1/20 (5) NR 0/20 (0)
Castelli et al (13)‡‡‡ 1/21 (5) 1/21 (5) NR 4/21 (19) NR - NR 2/21 (10) NR
Larzon et al (15)§§§ 4/26 (15) 6/26 (23) 0/26 (0) 4/26 (15) 4/26 (15) - NR 1/26 (4) NR
Franks et al (17)|||||| 6/22 (27) 7/22 (32) NR 3/22 (14) 2/22 (9) - NR 1/22 (5) 1/22 (5)
Pooled outcome 
(95%-CI)
0.16
(0.09-0.26)
0.24
(0.16-0.33)
0.07
(0.02-0.21)
0.18
(0.12-0.28)
0.13
(0.07-0.22)
- -
0.08
(0.03-0.16)
0.05
(0.01-0.18)
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The pooled proportion of total systemic complications (i.e., the sum of cardiac, pulmonary, cere-
brovascular, and renal complications, multiorgan failure, and sepsis) was 28% (95%-confidence 
interval 17–48%) for endovascular repair and 56% (95%-confidence interval 37–85%) for open 
surgery. 
Follow-up data were reported in 5 studies and only in patients treated with endovascular repair 
(8, 9, 11, 13, 17). Peppelenbosch et al reported type 1 endoleaks in two patients and a type 2 
endoleak in one patient during follow-up from 30 days to 14 months. Reichart et al reported an 
additional endovascular procedure to exclude an iliac aneurysm in one patient during follow-up 
from 6 to 24 months. Alsac et al reported a conversion to open surgery for endografts sepsis 
in one patient, type 1 endoleaks in three patients, and a second rupture in one patient during 
follow-up from 30 days to 250 days. Castelli et al reported an occlusion of an iliac limb in one 
patient and type 2 endoleaks in two patients during follow-up from 4 to 24 months. Franks et 
al reported type 2 endoleaks in 4 patients during follow-up from 7 to 106 months. It should be 
noted that Peppelenbosch et al and Franks et al did not report data on follow-up separately for 
patients with a symptomatic AAA and patients with a ruptured AAA. 
Funnel plot 
Publication bias was evaluated with a funnel plot (Figure 3). 
Figure 3: Funnel plot.
Funnel plot shows the reciprocal of the standard error of the 30-day mortality odds ratio, endovascular repair versus open surgery, as a 
function of the natural logarithm of the 30-day mortality odds ratio. The square with the horizontal bars indicates the natural logarithm 
of the pooled 30-day mortality odds ratio with the 95%-confidence interval. The funnel plot shows an asymmetrical distribution of the 
data points, indicating that publication bias may be present. In the lower right-hand corner, studies appear to be missing. This suggests 
that small studies with higher mortality rates for endovascular repair than for open surgery are underrepresented. ● = studies.
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DISCUSSION
In this systematic review, we reviewed and compared 10 articles that reported results of both 
endovascular repair and open surgery in patients treated for ruptured AAA. The results of our 
review demonstrated lower 30-day mortality and less postoperative systemic complications 
after endovascular repair than after open surgery. Among patients included in the studies, how-
ever, heterogeneity was found in patients’ hemodynamic condition upon their presentation 
to the hospital. Because a hemodynamic unstable condition may result in poorer clinical out-
come (22-24), we calculated a 30-day mortality odds ratio adjusted for patients’ hemodynamic 
condition. After adjustment, a benefit in 30-day mortality for endovascular repair compared to 
open surgery, was still demonstrated, however, the benefit was reduced and was not statistically 
significant anymore. 
Caution must be exercised when interpreting the results of this review. The principal limitation 
of our study was that no randomized controlled clinical trials were included and that only ob-
servational studies were available. Systematic reviews of observational studies may be a better 
representation of daily clinical practice than randomized controlled trials . In the comparison of 
therapies, however, it means that the studies included may have suffered from selection bias. 
The decision to treat patients with a ruptured AAA with endovascular repair or open surgery 
was based on patients’ hemodynamic condition upon presentation to the hospital, anatomical 
considerations, and/or logistic reasons, such as availability of adequate endovascular equipment 
and sufficiently trained staff. A selection based on patients’ hemodynamic condition may result 
in poorer clinical outcomes for open surgery, which was confirmed by our analysis in which we 
adjusted 30-day mortality for this condition. The effect of potential bias due to other selection 
criteria remains unknown, but is likely to be in favor of endovascular repair. 
Other major limitations of our review, as with many reviews, are variation in definitions and 
protocols across the studies and the quality of reported data. Across the studies in our review, 
procedure protocols varied, type of grafts used varied, definitions of characteristics and clinical 
outcomes varied, and sometimes definitions or data were not reported. This lack of standard-
ization in treatment protocol and reporting data complicated the comparison of endovascular 
repair and open surgery. In addition, over two times as many patients were treated with open 
surgery as with endovascular repair and complications. Furthermore, data on in-hospital com-
plications for both treatment groups were reported in only 5 of 10 included studies and data on 
follow-up were only available for patients treated with endovascular repair in 5 of 10 included 
studies. Nevertheless, showing the data of the studies in a systematic way and performing 
analyses with adjustment for a major confounder demonstrated current status of treatment 
management for patients with a ruptured AAA.
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Our study may have been affected by publication bias (i.e. the greater likelihood of publication 
of positive results or results based on large sample sizes). To investigate this bias we constructed 
a funnel plot. Our funnel plot was not symmetrically shaped, small studies with higher mortality 
rates for endovascular repair than for open surgery seemed to be underrepresented, which may 
have favored endovascular repair. It should be noted that our literature search was thorough; 
therefore it is unlikely that we missed relevant articles. We did, however, limit our search to the 
English language literature, based on a report that demonstrated that literature searches limited 
to the English literature often produce results that are close to results produced by comprehen-
sive searches with no language restriction (28, 29). 
Unfortunately, only small numbers are available for follow-up and the studies in our review 
did not report long-term follow-up. Thus, uncertainty remains concerning the long-term 
effectiveness of endovascular repair for patients with a ruptured AAA. In the long-run, threats 
to the effectiveness of endovascular repair are endoleaks, thrombosis, stenosis, and graft 
migration (30, 31). Therefore, a clinical benefit due to the favorable short-term results of endo-
vascular repair compared to open surgery may be negated when long-term follow-up is taken 
into account. Recently this was demonstrated in randomized controlled trials comparing clinical 
effectiveness of elective endovascular repair compared to open surgery in patients with asymp-
tomatic AAAs. The results of these trials suggested that the short-term reduction in mortality for 
patients treated with endovascular repair was not sustained after two years of follow-up (6, 7). In 
addition, in a time of budget constraints, costs or cost-effectiveness of a new therapy compared 
to the traditional therapy may influence treatment policy. Of note, a recently performed study 
on the costs of endovascular repair versus open surgery in patients with acute AAAs showed that 
endovascular repair was cost saving compared to open surgery, even after one-year follow-up 
(32). 
Furthermore, to avoid selection bias and enhance the comparability between the two treat-
ments, hemodynamically unstable patients should be excluded from the analysis. This will 
increase the homogeneity between patients treated with endovascular repair and patients 
treated with open surgery. Ideally, logistic reasons to treat patients with open surgery instead of 
endovascular repair should be avoided by having trained staff 24 hours a day, 7 days per week 
on call and adequate endovascular equipment on stock. To enable combining results of different 
studies reporting on endovascular repair and open surgery in patients with a ruptured AAA in a 
meta-analysis, we would recommend that researchers describe patient and procedure character-
istics, and selection criteria for endovascular repair in accurate detail (33-35). 
In conclusion, after adjustment for patients’ hemodynamic condition upon presentation, a ben-
efit in 30-day mortality for endovascular repair compared to open surgery for patients with a rup-
tured AAA was observed but was not statistically significant. For the decision whether patients 
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with ruptured AAA should be treated with endovascular repair or open surgery, more research is 
needed, especially larger series and longer follow-up with adequate reporting of data.
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ABSTRACT
Objective: To compare the clinical outcomes of treatment after endovascular repair and open 
surgery in patients with ruptured infrarenal abdominal aortic aneurysms (AAAs) including one-
year follow-up. 
Materials and methods: All consecutive conscious patients with ruptured infrarenal AAAs who 
presented to our tertiary-care teaching hospital between January 1, 2001 and December 31, 
2005 were included in this study (n = 55). Twenty-six patients underwent endovascular repair 
and 29 patients underwent open surgery. Patients who were hemodynamically too unstable 
to undergo a computed tomography scan were excluded. Outcomes evaluated were intra- 
operative mortality, 30-day mortality, systemic complications, complications requiring surgical 
intervention, and mortality and complications during one-year follow-up. The statistical tests 
we used were student t-test, χ2-test, Fisher’s Exact-Test, and Mann Whitney U-test (two-sided, 
α = 0.05). 
Results: Thirty-day mortality was 8/26 (31%) for patients who underwent endovascular repair 
and 9/29 (31%) for patients who underwent open surgery (p = 0.98). Systemic complications 
and complications requiring surgical intervention during the initial hospital stay were similar in 
both treatment groups (8/26 (31%) and 5/26 (19%) for endovascular repair, respectively, and 9/29 
(31%) and 8/29 (28%) for open surgery, respectively, p > 0.40). During one-year follow-up, two 
patients initially treated with endovascular repair died due to non-aneurysm related causes; no 
deaths occurred in the open surgery group. Complications during one-year follow-up were 1/20 
(5%) for endovascular repair and 4/25 (16%) for open surgery (p = 0.36). 
Conclusion: Based on our study with a highly selective population, the mortality and complica-
tion rates after endovascular repair may be similar compared to after open surgery in patients 
treated for ruptured infrarenal AAAs.
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INTRODUCTION
Mortality in patients with a ruptured abdominal aortic aneurysm (AAA) treated with open sur-
gery remains high. Among patients who arrive in the hospital alive and undergo open surgery, 
the reported mortality rates vary between 32% and 70%, and the morbidity rates vary between 
30% and 50% (1, 2). Since 1994, endovascular aneurysm repair in patients with a ruptured AAA 
has been proven to be feasible (3). Recently, this technique has become routine practice in 
Europe, and it is increasingly performed in the United States. Several studies have demonstrated 
a reduction in mortality and morbidity rates of endovascular repair compared with conventional 
open surgery in patients with ruptured AAAs (4-16). Most of these studies, however, included 
hemodynamically unstable patients in the open surgery group, whereas in the endovascular 
group mostly hemodynamically stable patients were included. To assess the clinical effective-
ness of endovascular repair and open surgery in patients with a ruptured AAA, it is essential 
to compare both treatments in a homogeneous group of patients. Therefore, in the absence of 
a randomized controlled clinical trial, we compared endovascular repair and open surgery in 
patients who were hemodynamically stable enough to undergo a computed tomography (CT)-
scan before the procedure.
Several advantages and disadvantages of endovascular repair over open surgery exist. Impor-
tant advantages of endovascular repair are potential avoidance of general anesthesia and mini-
mization of invasiveness. During endovascular repair, the aorta is not clamped, and blood loss 
is considerably less than with open surgery. Patients treated with endovascular repair, however, 
are expected to have complications in the long run as a result of graft failure, such as endoleak 
and graft migration (17-21). Therefore, follow-up after endovascular repair is essential. Patients 
treated with open surgery may have more severe complications during and immediately after 
the procedure, such as bleeding, cardiac and pulmonary complications, and ischemia of the 
sigmoid, whereas during follow-up complications are rare after open surgery. Thus, to evaluate 
the clinical effectiveness of both procedures, it is important to determine these complications 
both during the hospital stay and during follow-up. 
The objective of our study was to compare the clinical outcomes of treatment after endovascular 
repair and open surgery in patients with ruptured infrarenal AAAs, including 1-year follow-up. 
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MATERIALS AND METHODS
Patients and protocol
All consecutive patients treated for a ruptured AAA in our university-based tertiary care center 
between January 1, 2001 and December 31, 2005 were evaluated (n = 94). The study period 
started from 2001, because January 2001 marked the initiation of endovascular repair of rup-
tured AAAs in our hospital. To make comparable groups of patients treated with endovascular 
repair and patients treated with open surgery, we excluded patients with a juxtarenal or suprare-
nal AAA (necessitating suprarenal clamping; n = 26), those with an AAA unknown AAA anatomy 
(n = 2), and those who were hemodynamically too unstable (i.e., systolic blood pressure < 70 
millimeter Mercury and no adequate verbal reply) and therefore were unable to undergo a CT-
scan before the procedure (n = 11; Figure 1). 
Figure 1: Flowchart of patients with a ruptured Abdominal Aortic Aneurysm (AAA) included in 
analysis.
CT = computed tomography 
CLINICAL OUTCOMES WITH 1-YEAR FOLLOW-UP
39
Hemodynamically too unstable patients (n = 11) were immediately transported to the operating 
room, where they all underwent open surgery. In this study, 55 patients with ruptured infrarenal 
AAAs were included in the analysis.
The records of all patients with a ruptured AAA were identified from the medical registry by 
using operation codes. These codes are valid for our institution specifically. Patient data were 
obtained partly retrospectively and partly prospectively. Retrospectively data were retrieved 
from a computerized hospital database and, subsequently, from medical records. To obtain infor-
mation about patients’ readmissions, we verified patients’ medical records and the computerized 
database of our hospital or of the hospital to which they were readmitted. From December 2004 
onward, patients (n = 16) were prospectively enrolled in our study. Institutional Review Board 
approval was obtained, and informed consent to verify patient data was waived because we 
analyzed only patient data documented as part of routine clinical care and collected from the 
medical records. Note that in The Netherlands, patients’ formal written informed consent is not 
obtained for good clinical practice. Use of new or emerging therapies can be applied after Insti-
tutional Review Board approval of the hospital.
Once the emergency department was informed that a patient with a ruptured AAA was in trans-
port to the hospital, a team consisting of a vascular surgeon, an interventional radiologist, and 
an anesthesiologist was waiting for the patient in the emergency room. This team was available 
24 hours a day, 7 days a week. Upon the patient’s arrival in the emergency room, an abdominal 
ultrasound scan was performed to confirm the diagnosis of an AAA. Furthermore, an electrocar-
diogram was performed, and laboratory findings were assessed to determine the patient’s clini-
cal condition. Hemodynamically stable patients were transported to the CT-suite to perform an 
abdominal CT-scan to assess whether the AAA was ruptured or not and to decide whether the 
AAA was suitable for endovascular repair. An infrarenal AAA was considered ruptured in the pres-
ence of leakage on the preoperative CT-scan. The anatomic inclusion criteria for endovascular 
repair were a proximal neck >15 millimeter, neck diameter < 28 millimeter, angulation < 90º, and 
accessibility of the iliac arteries. After the CT-scan confirmed rupture of the AAA, the patient was 
immediately transported to the operating room, where endovascular repair was performed if the 
AAA was suitable; otherwise, open surgery was performed. In our protocol, the decision to treat 
patients with endovascular repair or open surgery was not based on intraoperative aortography 
only. Hemodynamically too unstable patients (n = 11) were immediately transported to the 
operating room for open surgery and were excluded from this analysis. The median time interval 
between arrival in the emergency room and arrival in the operating room was 43 minutes (range, 
15 minutes to 59 hours) for patients with a ruptured AAA. In total, in our analysis we included 55 
patients with a ruptured infrarenal AAA. One-year follow-up was completed for 45 patients who 
underwent operation between January 1, 2001, and December 31, 2005. 
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In patients treated with endovascular repair, 1 Cook (Zenith, Bloomington, Ind) and 24 Excluder 
(Gore, Flagstaff, Ariz) endografts were used. In patients treated with open surgery, Sulzer/Terumo 
(Vascutek, Renfrewshire, Scotland) vascular prostheses were used. In our local setting, a large 
variety of endografts and vascular prostheses is on stock. Endovascular repair of a ruptured AAA 
was performed in the operating room by a vascular surgeon (four involved; on average, 4 years 
of experience in endovascular AAA repair and 20 years of experience in open AAA repair, as of 
2001) and an interventional radiologist (two involved; on average, 4 years of experience in endo-
vascular AAA repair, as of 2001). Patients with ruptured AAAs who underwent endovascular re-
pair preferentially received local or regional anesthesia. According to our protocol, we accepted 
hypotension (i.e., systolic blood pressure < 90 millimeter Mercury) without massive fluid resusci-
tation (permissive hypotension) in order to prevent further bleeding. Patients treated with open 
surgery received general anesthesia. In patients treated with endovascular repair, a groin cut 
down was performed to obtain access to the common femoral artery. A bifurcated endograft 
was preferentially used. If iliac occlusions were present on one side, an aorto-mono-iliac endo-
graft was used. The first intraoperative angiography was performed only after the main body of 
the endograft was introduced. After completion of the endovascular procedure, control angio-
graphy was performed to exclude a type I or type III endoleak. A CT-scan was performed before 
discharge to assess complete exclusion of the AAA. If an endoleak was seen on the predischarge 
CT-scan, a reintervention was scheduled, and the patient was treated within 1 month. The man-
agement of early endoleaks was similar after ruptured AAA repair and after intact AAA repair. 
During follow-up, for patients who underwent endovascular repair, physician visits, and CT-scans 
were scheduled 3, 6, and 12 months after the initial procedure. For patients who underwent 
open surgery, physician visits were scheduled at 3 and 6 months, and at 6 months an ultrasound 
scan was performed.
Clinical outcomes
The outcomes evaluated were intraoperative mortality, 30-day mortality, systemic complica-
tions, complications necessitating surgical intervention, and mortality and complications during 
1-year follow-up. Surgical interventions included tracheostomy, bowel resection, and surgical 
evacuation of an access site hematoma or infection. 
We defined relevant comorbidity factors for patients with a ruptured infrarenal AAA based on 
published covariates in the literature (22-25). Comorbidity was assessed by one author by using 
the patients’ medical history. Patients were stratified using the Lee risk index (26). This index was 
used to identify patients at higher risk for cardiac complications after the procedure. Patients 
were assigned to risk class II, III, or IV, depending on the presence of a set of risk factors. Patients 
in a higher risk class had a greater risk of cardiac complications after the procedure than those 
in a lower risk class. Diabetes mellitus was defined as receiving either oral medication and/or 
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insulin therapy for diabetes mellitus. Ischemic heart disease included angina pectoris and myo-
cardial infarction in the medical history. Congestive heart failure included symptoms of conges-
tive heart failure and receipt of medication for this diagnosis. History of a cerebrovascular event 
included stroke or transient ischemic attack. Hypertension included a systolic blood pressure 
≥ 140 millimeter Mercury and/or a diastolic blood pressure ≥ 90 millimeter Mercury and receipt 
of at least one antihypertensive drug. Renal dysfunction included a creatine level > 2.0 milligram 
per deciliter. Chronic pulmonary disease included a forced expiratory volume in 1 second < 70%. 
Complications were identified by using the “Reporting Standards for Endovascular Aortic Aneu-
rysm Repair” of Chaikof et al (27). 
Data analysis
Patient and lesion characteristics, procedure data, and clinical outcomes during hospital stay and 
1-year follow-up of patients with ruptured AAAs who underwent endovascular repair and open 
surgery were compared by using the Student t-test, χ2-test, Fisher’s Exact-Test, and Mann Whit-
ney U-test (two-sided; α = 0.05). For data with a skewed distribution, we reported the median. 
Clinical results were calculated by taking all patients with a ruptured AAA (n = 55) into account, 
including patients who died. Data on mortality and morbidity were complete for all included 
patients. A few items related to the patient and procedure characteristics, however, were missing. 
In the tables, we identified the missing data; in total, < 1% of the data were missed. Analyses were 
performed by using Microsoft Excel 2000 (Microsoft Corporation, Redmond, Wash), and SPSS for 
Windows Version 11.0.1 (SPSS Inc., Chicago, Ill). 
RESULTS
Patient characteristics
Patient and lesion characteristics are listed in Table 1.
The mean AAA diameter was similar for patients who underwent endovascular repair and for 
those who received open surgery (74 millimeter versus 76 millimeter (p = 0.64) for endovascular 
repair and open surgery, respectively). Reasons to treat patients with open surgery were neck 
too short (n = 10), too much mural thrombus neck (n = 1), neck angulation > 90º (n = 5), conical 
neck (n = 4), inaccessible iliac tract (n = 4), aneurysm iliac tract (n = 2), and logistic reasons (n = 3). 
Upon arrival in the emergency room, four patients had systolic blood pressures < 90 millimeter 
Mercury (although they were not hemodynamically unstable), of whom two were treated with 
open surgery and two with endovascular repair. 
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Procedure
Table 2 shows procedure characteristics. 
Of all patients treated with endovascular repair, two patients were converted to open surgery 
during the procedure because of persistent blood loss, and one patient underwent a decom-
pression laparotomy for an abdominal compartment syndrome. All three of these patients died. 
Of the patients with persistent blood loss, the patient with persistent blood loss due to profuse 
bleeding of the lumbar arteries died during the procedure (i.e., intraoperative mortality rate was 
1 of 26 (4%) patients), and the patient with persistent blood loss due to a tear in the aortic wall 
near the proximal attachment died within 4 hours after the procedure. The patient with abdomi-
Table 1: Patient and lesion characteristics in patients with a ruptured Abdominal Aortic 
Aneurysm (n = 55) 
SD = standard deviation, mm = millimeter, CVA = cerebrovascular accident, mmHg = millimeter Mercury, ACE = angiotensin con-
verting enzyme 
* These data were missing for one patient who underwent open surgery.
† Upon arrival in the emergency room.
‡ No information on the use of beta-blockers was available for two patients who underwent endovascular repair and for one who 
underwent open surgery.
§ These data were missing for one patient who underwent endovascular repair and for one who underwent open surgery. 
Endovascular repair
n = 26
Open surgery
n = 29
P - value
Mean age in years (SD) 72.5 (8.4) 73.9 (7.9) 0.53
Male 25 (96%) 28 (97%) 0.51
Mean AAA diameter in mm (SD) 74 (13) 76 (16) 0.61
Diabetes mellitus 1 (4%) 0 (0%) 0.47
Ischemic heart disease* 7 (27%) 6 (21%) 0.64
Congestive heart failure* 2 (8%) 1 (4%) 0.37
History of CVA* 4 (15%) 2 (7%) 0.22
Hypertension* 13 (50%) 12 (43%) 0.60
Renal dysfunction* 5 (19%) 2 (7%) 0.14
Chronic pulmonary disease* 7 (27%) 5 (18%) 0.42
Systolic blood pressure < 90 mmHg† 2 (8%) 2 (7%) 0.39
Medication
Beta-blockers‡ 6 (25%) 8 (29%) 0.77
Statins§ 4 (16%) 0 (0%) 0.04
Antiplatelet agents§ 4 (16%) 9 (32%) 0.17
ACE inhibitors§ 5 (20%) 4 (14%) 0.25
Calcium-channel blockers§ 0 (0%) 2 (7%) 0.27
Anticoagulants§ 5 (20%) 3 (11%) 0.20
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nal compartment syndrome died 13 days after the initial procedure as a result of sepsis. In addi-
tion to these three conversions, one failure occurred because no access was obtained as a result 
of calcified iliac arteries. Conversion to open surgery was offered to this patient, but she refused 
open surgery and subsequently died. One patient initially treated with endovascular repair un-
derwent a decompression laparotomy 7 hours after the initial procedure because of a suspected 
abdominal compartment syndrome. This patient died 4 days after the initial procedure as a re-
sult of respiratory insufficiency. No additional procedures were performed during endovascular 
repair. 
During open surgery, four of 29 (14%) patients died as a result of persisting blood loss (coagu-
lopathy leading to continued bleeding (n = 1), nonidentifiable venous bleeding (n = 1), diffuse 
bleeding after admitting heparine and local thrombolysis with medicinase (n = 1), and bleeding 
leading to no cardiac output (n = 1)). Additional procedures were performed in five patients 
during open surgery: resection of the sigmoid (n = 2), thrombectomy of the superficial femoral 
artery (n = 1), local endarterectomy of the common femoral artery (n = 1), and treatment of a 
scrotal hernia (n = 1). The median blood loss was lower with endovascular repair compared with 
that with open surgery (< 100 milliliter versus 6750 milliliter; p < 0.001).
Table 2: Procedure data in patients with a ruptured Abdominal Aortic Aneurysm
ml = milliliter, e.c. = erytrocytes concentrate, FFP = fresh frozen plasma 
* In one patient who underwent endovascular repair no access was obtained because of calcified iliac arteries. This patient refused 
conversion to open surgery and subsequently died; one patient who underwent open surgery died before graft placement.
Endovascular repair
n = 26
Open surgery
n = 29
P - value
General anesthesia 12 (46%) 29 (100%) <0.001
Tubular graft 1 (4%)* 19 (66%)* <0.001
Bifurcated graft 24 (92%)* 9 (31%)* <0.001
Conversion to open surgery during initial procedure 3 (12%) - -
Technical failure during initial procedure 4 (15%) - -
Additional procedures during initial procedure 0 (0%) 5 (17%) 0.04
Intraoperative mortality 1 (4%) 4 (14%) 0.18
Median blood loss in ml (range) <100 (<100-30000) 6750 (<100-31000) <0.001
Median transfusions units e.c. (range) 1.5 (0-27) 10 (0-31) <0.001
Median transfusions units FFP (range) 0 (0-20) 10 (0-45) <0.001
Median transfusions units platelet (range) 0 (0-15) 5 (0-20) <0.001
Median procedure time (range) 149 (79-400) 232 (40-434) <0.001
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Outcomes
In total, 8 of 26 (31%) patients and 9 of 29 (31%) patients treated with endovascular repair and 
open surgery, respectively, died within 30 days after the initial procedure (p = 0.98; Table 3). 
In addition to the patient who died intraoperatively during endovascular repair, 7 patients died 
within 30 days. The causes of postoperative death were persistent blood loss (i.e., due to a tear 
Table 3: Mortality, complications, and admissions in patients with a ruptured 
Abdominal Aortic Aneurysm
SD = standard deviation, ICU = intensive care unit
* Complications requiring surgical intervention included surgical evacuation of an access site hematoma or infection, tracheos-
tomy, and bowel resection.
† Systemic complications included cardiac arrest, progressive heart failure with fatal outcome, pulmonary complications requiring 
tracheostomy or with fatal outcome, pulmonary embolism requiring anticoagulation therapy or with fatal outcome, renalcompli-
cations requiring temporary dialysis, sepsis, and deep venous thrombosis.
‡ requiring surgical evacuation. 
§ requiring operative drainage. 
¶ cardiac arrest and progressive heart failure with fatal outcome. 
||requiring tracheostomy or pulmonary complications with fatal outcome. 
** requiring anticoagulation therapy or with fatal outcome. 
†† requiring temporary dialysis. 
‡‡ requiring bowel resection.
§§ One patient had a type 1 endoleak and was treated within one month after the initial procedure One patient had a type 3 
endoleak and was treated two months after the initial procedure.  Three patients had type 2 endoleaks. They were treated con-
servatively and their endoleaks disappeared spontaneously. None of these 3 patients were treated for endoleaks during one-year 
follow-up.
Endovascular repair
n = 26
Open surgery
n = 29
P - value
Intraoperative mortality 1 (4%) 4 (14%) 0.18
30-day mortality 8 (31%) 9 (31%) 0.98
Complications requiring surgical intervention* 5 (19%) 8 (28%) 0.47
Systemic complications† 8 (31%) 9 (31%) 0.98
Access site hematoma‡ 2 (8%) 3 (10%) 0.34
Access site infection§ 0 (0%) 3 (10%) 0.14
Cardiac complications¶ 3 (12%) 1 (3%) 0.22
Pulmonary complications|| 2 (8%) 2 (7%) 0.39
Pulmonary embolism** 2 (8%) 1 (3%) 0.36
Renal complications†† 0 (0%) 1 (3%) 0.53
Sepsis 3 (12%) 3 (10%) 0.33
Deep venous thrombosis** 0 (0%) 2 (7%) 0.27
Bowel ischemia‡‡ 1 (4%) 2 (7%) 0.40
Endoleak 5 (19%)§§ - -
Mean (SD), median
Postoperative days in the ICU 4.3 (8.6), 0.9 11.7 (15.0), 5.5 0.01
Postoperative days in hospital 10.9 (17.4), 4.0 26.7 (28.3), 15.3 0.003
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in the aortic wall near the proximal attachment; n = 1), sepsis (n = 1), respiratory insufficiency 
(n = 1), pulmonary embolism (n = 1), ventricular fibrillation (n = 1), progressive heart failure 
(n = 1), and technical failure of the endovascular procedure with refusal of conversion to open 
surgery, leading to death (n = 1). During the hospital stay, one patient who underwent endo-
vascular repair died 35 days after the initial procedure as a result of sepsis. In addition to the 
4 patients who died intraoperatively during open surgery, 5 patients died within 30 days. The 
causes of postoperative death were septic shock (n = 2), renal insufficiency (n = 1), respiratory 
insufficiency (n = 1), and progressive heart failure (n = 1). During the hospital stay, one patient 
who underwent open surgery died 109 days after the initial procedure as a result of the inability 
to wean the patient from mechanical ventilation.
Systemic complications and complications necessatating surgical intervention were not differ-
ent between treatment groups. In patients treated with endovascular repair, 1 patient required 
tracheotomy for respiratory failure. In patients treated with open surgery, 2 patients required 
tracheotomy for respiratory failure. Table 3 shows postoperative complications in more detail. 
The mean postoperative days in the intensive care unit (ICU) was 4.3 and 11.7 for endovascular 
repair and open surgery, respectively (p = 0.01). In total, the mean number of postoperative days 
in the hospital was 10.9 for endovascular repair and 26.7 for open surgery (p = 0.003; Table 3). 
In the endovascular repair group, one patient was discharged to a nursing hospital. In the open 
surgery group, three patients were discharged to a nursing hospital.
In table 4 we stratified 30-day mortality and systemic complications by the Lee risk index. 
For patients in Lee risk class II (i.e., those at a lower risk for cardiac complications), 30-day mortal-
ity and systemic complication rates were higher for endovascular repair compared with open 
surgery, although not statistically significant. For patients in Lee risk class III and IV (i.e., those at 
Table 4: In-hospital systemic complications and 30-day mortality in patients with a ruptured 
Abdominal Aortic Aneurysm stratified by the Lee risk index
* Systemic complications included cardiac arrest, progressive heart failure with fatal outcome, pulmonary complications requiring 
tracheostomy, pulmonary embolism requiring anticoagulation therapy, renal complications requiring temporary dialysis, sepsis, 
and deep venous thrombosis.
Endovascular repair Open surgery 
Lee risk index 30-day 
mortality
Systemic 
complications*
Lee risk index 30-day 
mortality
Systemic 
complications*
Class II  (n=13) 4 (31%) 5 (38%) Class II  (n=19) 4 (21%) 4 (21%)
Class III (n=8) 3 (38%) 2 (25%) Class III (n=7) 3 (43%) 3 (43%)
Class IV (n=5) 1 (20%) 1 (20%) Class IV (n=2) 1 (50%) 1 (50%)
Missing  (n=0) 0 0 Missing  (n=1) 1 1
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a higher risk for cardiac complications), 30-day mortality and systemic complication rates were 
lower for endovascular repair compared with open surgery (Table 4).
One-year follow-up
One-year follow-up was completed for 45 (82%) of 55 patients (Table 5).
During follow-up, two patients who were initially treated with endovascular repair died as a 
result of non-aneurysm related causes (i.e., pulmonary infection and cancer). One patient ini-
tially treated with endovascular repair and two patients initially treated with open surgery were 
readmitted to the hospital because of aneurysm-related complications. The patient treated with 
endovascular repair was readmitted for endovascular repair of a type 1 endoleak that was detect-
ed during the initial hospital stay. The patients treated with open surgery had aneurysm repair of 
the femoral artery and back pain suggestive of aneurysm-related problems. 
Juxtarenal AAA and hemodynamically unstable patients
For patients with juxtarenal AAAs, the intraoperative mortality was 4/26 (15%) and the 30-day 
mortality was 9/26 (35%). One-year follow-up was completed for 25 patients, of whom 11 (44%) 
died within 1 year. For patients who were hemodynamically too unstable to undergo a CT-scan 
before the procedure, the intraoperative mortality was 1/11 (9%), and the 30-day mortality was 
4/11 (36%). One-year follow-up was completed for 10 patients, of whom 5 (50%) died within 1 
year.
Table 5: One-year follow-up of patients with a ruptured Abdominal Aortic Aneurysm
* Type 2 endoleaks diagnosed at 4 months; they were treated conservatively. 
† After endovascular repair: a false aneurysm at 3 months, treated conservatively, n=1. After open surgery: aneurysm of the femoral 
artery at 4 months, readmitted for aneurysm repair, n=1; scar hernia at 6 months, treated conservatively, n=1; abdominal hernia 
at 7 months, treated conservatively, n=1; back pain suspected for aneurysm related problems at 8 months, readmitted, treated 
conservatively, n=1.
‡ This patient was readmitted for repair of a type 1 endoleak that was detected during the initial hospital stay.
§ Non-aneurysm related death.
Endovascular repair
n = 20
Open surgery
n = 25
P - value
Patients at risk 14 16 -
Median number of visits (range) 2.0 (0-6) 2.0 (0-6) 0.66
Median number of CTA’s (range) 1.5 (0-3) 0.0 (0-1) < 0.001
New diagnosed endoleaks* 2 (10%) - -
Complications† 1 (5%) 4 (16%) 0.21
Readmissions 1 (5%)‡ 2 (8%) 0.42
Died during follow-up 2 (10%)§ 0 (0%) 0.19
Total deaths at one year follow-up 8 (40%) 9 (36%) 0.78
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DISCUSSION
Endovascular repair has become an increasingly performed alternative to open surgery in 
patients with ruptured infrarenal AAAs. In our study, we compared clinical outcomes of patients 
treated with endovascular versus patients treated with open surgery. In the absence of random-
ization, we focused our comparison on hemodynamically stable patients to make the treatment 
groups more homogeneous and the comparison more adequate. In our treatment groups, 
the selection between endovascular repair and open surgery was based on anatomic criteria. 
Patients who were eligible (i.e., had suitable anatomy) for endovascular repair received this 
treatment; patients whose aneurysm anatomy was not suitable for endovascular repair 
received open surgery. Note that, in our hospital, vascular surgeons and interventional radi-
ologists are available 24 hours a day, 7 days a week, and that endografts are always on stock. 
The principal finding of our study was that 30-day mortality and morbidity were similar for 
endovascular repair and open surgery in patients with a ruptured AAA; this similarity was sus-
tained after 1-year follow-up. 
Results from the stratification suggested that patients with a lower risk for cardiac complica-
tions (i.e., Class II) had a better chance to survive and less morbidity after open surgery than 
after endovascular repair. In addition, patients with a higher risk for cardiac complications (i.e., 
Class III and IV) were better off with endovascular repair than with open surgery. It should be 
acknowledged that 50% of the patients treated with endovascular repair and 32% of the patients 
treated with open surgery were considered at high risk for cardiac complications (Class III and IV). 
Therefore, it seems that selection criteria other than aneurysms anatomy may have played a role 
in the treatment choice. It should be noted, however, that these thoughts are highly speculative 
because of the low number of patients and the highly selected population. 
So far, to our knowledge, no randomized controlled trial comparing endovascular repair and 
open surgery in patients with ruptured AAAs has been published. In other studies comparing 
the outcomes of endovascular repair and open surgery in patients with a ruptured AAA, results 
showed lower mortality for endovascular repair than was found in our study (5-16). Most of these 
studies, however, did not report on patients’ comorbidity. Therefore, it remains unclear whether 
this difference in mortality was due to differences in case mix. Furthermore, most other studies 
reported higher mortality rates for patients treated with open surgery compared with what we 
found. These studies included hemodynamically unstable patients who received open surgery 
and were not eligible for endovascular repair, whereas we excluded those patients. A recently 
published study in which the proportion of hemodynamically unstable patients was equal in 
both treatment groups showed similar results with our study (28). In addition, follow-up results 
reported in most other studies demonstrated more complications after endovascular repair than 
after open surgery because of graft related problems such as graft migration and endoleak, 
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whereas in our study, the complication rates in follow-up were similar for endovascular repair 
and open surgery (17-21). 
The results of our study should be interpreted with caution because of several limitations. The 
patients in our study were not randomly assigned to endovascular repair and open surgery, the 
sample sizes of both treatment groups were small, and follow-up was limited to 1 year. Despite 
these limitations, however, our study was a first attempt for a fair comparison in a time when 
endovascular repair is increasingly performed and data on effectiveness are needed. It is clear 
that more research comparing endovascular repair with open surgery in patients with ruptured 
AAAs in larger series with longer follow-up is needed, as suggested in the long-term effective-
ness of the trials in elective AAAs (29, 30). As far as we know, one randomized controlled trial is 
ongoing (31), but it may take years before results are available. Because endovascular repair is 
increasingly performed, data from solid research are needed at this time.
In addition, more research focusing on selection criteria and survival chances needs to be per-
formed. As in our study, among patients initially treated with endovascular repair, two were con-
verted to open surgery, and two underwent a decompression laparotomy. All of these patients 
died. Whether the patients’ comorbidities, AAA anatomy, or the delay caused by first perform-
ing endovascular repair instead of open surgery played a role in their survival chances remains 
unknown. These findings, however, do emphasize the need for a predictive tool that can identify 
patients who may benefit from endovascular repair and those who are unlikely to benefit from 
this procedure. 
In conclusion, on the basis of our study with a highly selected population, mortality and morbid-
ity may be similar for patients with ruptured infrarenal AAAs treated with endovascular repair 
compared with open surgery, even after 1-year follow-up. In addition to the aneurysm anatomy, 
other criteria may be needed for endovascular repair to improve clinical outcomes. To obtain 
more evidence regarding whether endovascular repair or open surgery is better in selected 
patients with a ruptured infrarenal AAA, more research is needed. 
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ABSTRACT
Purpose: To validate the Glasgow Aneurysm Score (GAS) in patients with ruptured abdominal 
aortic aneurysms (AAAs) treated with endovascular repair or open surgery and to update the 
GAS into the Dutch Aneurysm Score (DAS) that predicts 30-day mortality for patients with rup-
tured abdominal aortic aneurysm (AAA) treated with endovascular repair or open surgery. 
Materials and methods:  In a multicenter prospective observational study, 233 consecutive pa-
tients with ruptured AAA were evaluated. All patients who were treated with endovascular repair 
(n = 58) or open surgery (n = 143) were included. The GAS was calculated for each patient. The 
area under the receiver operating characteristics curve (AUC) was used to indicate discriminative 
ability. We tested for interactions between risk factors and the procedure performed. The GAS 
was updated to predict 30-day mortality after endovascular repair or open surgery in patients 
with ruptured AAA using logistic regression analysis and resulted in the DAS. 
Results: Thirty-day mortality was 15/58 (26%) for patients treated with endovascular repair and 
57/143 (40%) for patients treated with open surgery (p = 0.06). The AUC for GAS was 0.686. No 
relevant interactions were found. The DAS (AUC = 0.683) can be calculated with the following 
formula: + 3 if hemodynamically unstable prior to the procedure - 9 for endovascular repair + 
age in years + 17 for shock  + 7 for myocardial disease + 10 for cerebrovascular disease + 14 for 
renal disease. 
Conclusion: We showed limited discriminative ability of the GAS and therefore updated the GAS 
by adding patients’ hemodynamic stability prior to the procedure and the type of procedure 
performed. This DAS predicts 30-day mortality for patients with ruptured AAAs treated with 
endovascular repair or open surgery. 
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INTRODUCTION
The traditional approach to treat ruptured abdominal aortic aneurysms (AAA) is open surgery. 
The Glasgow Aneurysm Score (GAS) is used to predict in-hospital mortality after open surgery for 
patients with ruptured or unruptured AAA (1). Several studies have validated this prediction rule 
in patients with ruptured AAA treated with open surgery. Two validations reported good validity 
(2, 3) and one reported poor validity (4). 
Since 1994, endovascular repair for ruptured AAA has been proven to be feasible (5) and is 
increasingly being adopted as the treatment of choice (6). Several studies showed a reduction 
in mortality and morbidity rates after endovascular repair compared to rates for open surgery in 
patients with ruptured AAAs (7-10); however, in other studies this reduction could not be con-
firmed (11-13). Recently, it was suggested that patients at higher risk for peri-procedural cardiac 
complications may benefit more from endovascular repair than from open surgery (13).
Due to the rise of endovascular repair, the patient population receiving open surgery has shifted 
in recent years, and the GAS may no longer be valid in this population. Additionally, the GAS 
cannot be used to decide whether a patient with a ruptured AAA may benefit more from en-
dovascular repair or from open surgery, as it does not predict outcomes for endovascular repair 
patients. Whether the current GAS prediction rule is still valid in predicting 30-day mortality after 
open surgery and whether it can predict 30-day mortality after endovascular repair needs to be 
determined. Ideally, the GAS should be modified to identify patients who would be better suited 
for endovascular repair versus open surgery.  
The purpose of our study was to validate the GAS in patients with ruptured AAA who were 
treated with endovascular repair or open surgery. In addition, we aimed to update the GAS into 
the Dutch Aneurysm Score (DAS) for prediction of 30-day mortality after endovascular repair or 
open surgery.
MATERIALS AND METHODS
Patient population
In a prospective multicenter observational study, data were collected on 233 consecutive 
patients between December 22, 2004 and October 31, 2006 in seven institutions in the Nether-
lands: Atrium Medical Center, Heerlen (45 patients), Catharina Hospital, Eindhoven (25 patients), 
Erasmus MC, Rotterdam (40 patients), Medical Spectrum Twente, Enschede (24 patients), Medical 
Center Rotterdam Zuid, Rotterdam (30 patients), University Medical Center, Groningen (37 pa-
tients), and University Medical Center, Nijmegen (32 patients). Patients were included if they pre-
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sented with ruptured AAA and were treated with endovascular repair or open surgery (n = 201). 
A total of 32 of 233 patients (14%) were excluded because they died before AAA repair could be 
initiated; death was caused by severe comorbidity or the patient refused treatment (Figure 1).
Rupture of the AAA was confirmed on CT-scan or angiography prior to the procedure, or by free 
blood noted during laparotomy. The Institutional Review Board approved this study and waived 
the obligation to obtain informed consent due to the acute nature of the clinical problem and 
the observational nature of this study (14).
Protocol
In all participating hospitals, endovascular repair was the preferred treatment in patients with 
ruptured AAA. Except for in one hospital, the vascular surgeon and/or radiologist who performed 
endovascular repair of ruptured AAA were available 24 hours a day, 7 days a week. Upon arrival in 
the hospital, patients who were in a hemodynamically stable condition underwent an abdominal 
CT-scan or aortic angiography to confirm rupture and to assess whether the AAA was anatomi-
cally suited for endovascular repair. Hemodynamically unstable patients (n = 37) were immedi-
ately transported to the operating room for open surgery. The definition of “hemodynamically 
Figure 1: Patient flowchart
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stable” varied across the participating hospitals. In two hospitals, the attending vascular surgeon 
made the judgment without explicit criteria. In two other hospitals, the attending vascular sur-
geon or radiologist considered the patient hemodynamically stable if (s)he gave an adequate 
verbal reply. In one hospital, the attending vascular surgeon defined hemodynamically stable 
as a systolic blood pressure of 60 millimeter Mercury or higher, whereas in two other hospitals 
a systolic blood pressure cutoff of 70 millimeter Mercury was used. After CT-scan or angiogra-
phy confirmed the presence of a ruptured AAA, the patient was immediately transported to the 
operating room where endovascular repair was performed if the AAA was anatomically suitable; 
otherwise, open surgery was performed. The anatomic inclusion criteria for endovascular repair 
differed between the participating hospitals since they stocked different endovascular devices. 
The criteria varied between 7 and 15 millimeter for the proximal neck length, between 30º and 
90º for the neck angulation, and between 28 and 32 millimeter for the neck diameter. The endo-
grafts used were Talent aortouniiliac (AUI) stent-grafts (Medtronic, Santa Rosa, CA), ANACONDA 
bifurcated endografts (Vascutek, Renfrewshire, Scotland), Cook endografts (Zenith, Blooming-
ton, IN), and Excluder endografts (Gore, Flagstaff, AZ).
Data collection and definitions
Prospectively collected data included: patient characteristics (i.e., age, sex, renal failure, and 
history of diabetes mellitus, hypertension, angina pectoris, myocardial infarction, congestive 
heart failure, or cerebrovascular disease), use of medication prior to hospital admission, patients’ 
hemodynamic condition upon presentation to the hospital, shock upon presentation to the hos-
pital, use of CT-scan or angiography prior to the procedure, morphology of the AAA (infrarenal, 
juxtarenal, or suprarenal), and which treatment was performed (endovascular repair or open sur-
gery). Shock was defined as a systolic blood pressure less than 80 millimeter Mercury. Myocardial 
disease comprised previous myocardial infarction and/or angina pectoris. Cerebrovascular dis-
ease included all previous cerebrovascular accidents and transient ischemic attacks. Renal failure 
referred to a preoperative creatinine value more of than 160 micromol per liter (i.e., 1.8 milligram 
per deciliter). A standardized form was used to register these data. In order to obtain informa-
tion about 30-day mortality, medical records and the computerized database of the participating 
hospitals were used. 
Glasgow Aneurysm Score
The GAS was originally based on 235 patients treated for AAA between January 1980 and 
December 1989 at 4 hospitals in Glasgow, United Kingdom (1). The GAS was calculated using the 
following formula: GAS = age in years + 17 for shock + 7 for myocardial disease + 10 for cerebro-
vascular disease + 14 for renal disease (1). Patients with a GAS less than 70 are considered to have 
a low risk of mortality after open surgery for AAA, whereas patients with a GAS more than 85 are 
considered to have a high risk of mortality after treatment for AAA. In the original paper, ‘shock’ 
was based on clinical information of tachycardia, hypotension, pallor, and sweating. Myocardial 
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disease was defined as previous myocardial infarction and/or angina pectoris. Cerebrovascular 
disease comprised all grades of stroke including transient ischemic attacks. Renal disease includ-
ed chronic and acute renal failure (1). 
Data and statistical analyses
Patient data were entered into a database and checked by one of the authors for completeness 
(author initials blinded). Missing data regarding continuous variables (i.e., age and systolic blood 
pressure) were assumed to be missing at random and entered based on the variable means. If 
data regarding patients’ medical history or medication were missing, it was assumed that the risk 
factor was not present or the medication was not used. In total, the proportion of missing data 
was less then 2%. Analyses were performed according to the intention-to treat principle.
We validated the GAS using receiver operating characteristics (ROC) curves to determine dis-
criminative ability (i.e., whether the GAS was higher in patients who died). An area under the ROC 
curve (AUC) of 0.50 indicates no discriminative ability and the closer the AUC is to 1.0, the better 
the discriminative ability. 
In addition, we tested for interactions between risk factors (as determined in the GAS model) 
and the specific procedure performed in predicting 30-day mortality using logistic regression 
analysis. Interaction terms were considered potentially relevant if p < 0.20.
Based on a previously published approach, the GAS was updated to predict 30-day mortality 
after either endovascular repair or open surgery (15). In the first step, we estimated new regres-
sion coefficients for the GAS variables based on the Dutch data. In the second step, we added 
patients’ hemodynamic stability prior to the procedure and the procedure performed (endovas-
cular repair versus open surgery) to the original GAS variables (15). Regression coefficients for 
the new variables (i.e. patients’ hemodynamic stability and the procedure) and an intercept term 
were estimated; the GAS was then multiplied by a calibration slope βGAS for overall adjustment 
of the original GAS regression coefficients. The formula we used was: (30-day mortality)Dutch data = 
α + βhemodynamic stability * (patients’ hemodynamic stability) + βprocedure * (procedure) + βGAS * GAS. To 
calculate the adjusted GAS odds ratios, we used the formula: (adjusted GAS odds ratio) = (original 
GAS odds ratio) * exp (βGAS). In the third step, we performed a multivariable logistic regression 
analysis on 30-day mortality, including patients’ hemodynamic stability prior to the procedure, 
the procedure performed (endovascular repair versus open surgery), and all individual GAS vari-
ables (i.e., age, shock, myocardial disease, cerebrovascular disease, and renal disease), and we es-
timated new regression coefficients for each variable (15). For each step, the AUC was estimated 
as a measure of discriminative ability and adjusted for optimism by bootstrapping. We used 200 
bootstrap samples drawn with replacement from the original data set. This validation procedure 
indicates the performance that may be expected in new, but similar patients (16). The AUCs from 
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the first, second, and third step were compared, and the prediction rule with the highest AUC is 
presented as the updated prediction rule: the DAS. 
Analyses were performed using SPSS for Windows Version 11.0.1 (SPSS Inc., Chicago, IL) and 
S-Plus Version 6.0 (Insightful Corporation, Seattle, WA).
RESULTS
Patient population
Patient demographics, characteristics and use of medication before admission are listed in 
Table 1. 
The proportion of males was somewhat higher in patients treated with endovascular repair com-
pared with patients treated with open surgery (93% versus 83%, p = 0.05). Shock occurred more 
often in patients treated with open surgery compared with patients treated with endovascular 
repair (28% versus 7%, p = 0.001). In addition, the use of statins was somewhat higher in patients 
treated with endovascular repair compared with patients treated with open surgery (31% versus 
19%, p = 0.06). The other characteristics were similar between the treatment groups. All of the 58 
patients treated with endovascular repair had infrarenal AAAs. Eighty-three of the 143 patients 
(58%) treated with open surgery had infrarenal AAAs, 49 (34%) had juxtarenal AAAs, 4 (3%) had 
suprarenal AAAs, and in 7 patients (5%) the AAA anatomy was not reported.
Outcomes
Thirty-day mortality was 15/58 (26%) for patients treated with endovascular repair and 57/143 
(40%) for patients treated with open surgery (p = 0.06). Among patients who were treated with 
open surgery, 30-day mortality was 39/106 (37%) for those who were hemodynamically stable 
prior to the procedure and 18/37 (49%) for those who were hemodynamically unstable prior to 
the procedure (p = 0.20). Two of the 58 patients (3%) treated with endovascular repair died intra-
operatively, while 21 of the 143 patients (15%) treated with open surgery died intraoperatively 
(p = 0.02). The causes of 30-day mortality are listed in Table 2. 
Nine of the 58 patients (16%) initially treated with endovascular repair were converted to open 
surgery. 
Validation of GAS 
The GAS was less than 70 in 42 patients; between 70 and 75 in 26 patients; between 76 and 85 in 
58 patients; and more than 85 in 75 patients (Table 3). 
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The mean GAS among patients who survived 30 days after the initial procedure was 77 for pa-
tients treated with endovascular repair and 80 for patients treated with open surgery (p = 0.14). 
The mean GAS among patients who died within 30 days after the initial procedure was 87 for pa-
tients treated with endovascular repair and 88 for patients treated with open surgery (p = 0.81). 
The AUC for the GAS was 0.686 (95%-confidence interval 0.612 – 0.761). 
Interaction
Testing for interaction between risk factors and the type of procedure performed on 30-day 
mortality showed no relevant interactions (all p-values > 0.20). This means that, considering the 
included variables, 30-day mortality was always lower if patients with ruptured AAA were treated 
with endovascular repair instead of open surgery.
Table 1: Patient demographics and characteristics
SD = standard deviation, CVA = cerebrovascular accident, TIA = transient ischemic attacks, COPD = chronic obstructive pulmonary 
disease, AAA = abdominal aortic aneurysm
Endovascular repair 
n = 58
Open surgery 
n = 143
P-value
Male 54 (93%) 118 (83%) 0.05
Mean age (SD) 73.2 (8.6) 73.5 (7.5) 0.83
Renal failure 8 (14%) 16 (11%) 0.61
Diabetes mellitus 8 (14%) 13 (9%) 0.32
Hypertension 29 (50%) 60 (42%) 0.30
Angina pectoris 6 (10%) 18 (13%) 0.66
Previous myocardial infarction 12 (21%) 35 (25%) 0.57
Heart failure 6 (10%) 14 (10%) 0.91
CVA/TIA 6 (10%) 18 (13%) 0.66
COPD 15 (26%) 30 (21%) 0.45
AAA known before admission 14 (24%) 25 (18%) 0.28
Shock 4 (7%) 40 (28%) 0.001
Medication
Beta-blocker 19 (33%) 40 (28%) 0.50
Antiplatelet agents 11 (19%) 17 (12%) 0.19
Aspirin 24 (41%) 46 (32%) 0.21
Statins 18 (31%) 27 (19%) 0.06
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Updated prediction rule
In the first step, we estimated new regression coefficients for the GAS variables based on the 
Dutch data. The AUC adjusted for optimism was 0.673 (Table 4). In the second step, we added 
2 new variables to the original GAS variables: patients’ hemodynamic stability prior to the pro-
cedure and the type of procedure performed (endovascular repair versus open surgery). The 
Table 2: Causes of 30-day mortality
* Cardiac causes of death included ventricular fibrillation, myocardial ischemia, progressive heart failure with fatal outcome, con-
tinuous hypotension, and cardiac arrest.
† Pulmonary causes of death included acute respiratory distress syndrome, pulmonary embolism, and respiratory insufficiency. 
‡ Shock included septic shock, hypovolemic shock, and cardiac shock.
§ Due to patients’ comorbidity, no further medical support was given.
Endovascular repair n = 58 Open surgery n = 143
Intraoperative 2 (3%) 21 (15%)
Postoperative
      Cardiovascular* 3 (5%) 8 (6%)
      Pulmonary† 3 (5%) 5 (3%)
      Renal failure 1 (2%) 1 (1%)
      Sepsis 2 (3%) 1 (1%)
      Shock‡ 2 (3%) 4 (3%)
      Coagulopathy 1 (2%) 0 (0%)
      Multiorgan Failure 1 (2%) 4 (3%)
      Infection 0 (0%) 1 (1%)
      No treatment due to patients’ comorbidity§ 0 (0%) 3 (2%)
      Unknown 0 (0%) 9 (6%)
Total deaths 15 (26%) 57 (40%)
Table 3: GAS and the prediction of 30-day mortality
GAS = Glasgow Aneurysm Score, CI = confidence interval
* Open surgery versus endovascular repair
Endovascular repair Open surgery Odds ratio* (95%-CI)
Score Number of 
patients
Mortality (%) Number of 
patients
Mortality (%)
 < 70 17 2 (12%) 25 3 (12%) 1.02 (0.15-6.9)
70-75 8 2 (25%) 18 7 (39%) 1.91 (0.30-12)
76-85 16 3 (19%) 42 17 (41%) 2.95 (0.73-12)
> 85 17 8 (47%) 58 30 (52%) 1.21 (0.41-3.6)
Total 58 15 (26%) 143 57 (40%) 1.90 (0.97-3.7)
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estimation of the intercept, regression coefficients, and calibration slope led to the following 
formula: 
(30-day mortality)Dutch data  =  – 4.76 + 0.17 * (patients’ hemodynamic stability) - 0.46 * (procedure) 
+ 0.051 * GAS. The AUC adjusted for optimism was 0.683. The adjusted GAS odds ratios are listed 
in Table 4. 
In the third step, patients’ hemodynamic stability prior to the procedure and the type of proce-
dure performed (endovascular repair versus open surgery) were added to the GAS variables, and 
new regression coefficients were estimated for each variable. The AUC was adjusted for optimism 
by bootstrapping and was 0.679. Since the second model had the highest optimism-corrected 
AUC, we used it to calculate the Dutch Aneurysm Score (DAS). Multiplication with the weights in 
the original GAS and rounding gives the following risk score: 
DAS = + 3 if hemodynamically unstable prior to the procedure - 9 for endovascular repair + age 
in years + 17 for shock  + 7 for myocardial disease + 10 for cerebrovascular disease + 14 for renal 
disease. 
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Table 5 shows an example of how to calculate the 30-day mortality for a patient with a ruptured 
AAA for endovascular repair or open surgery.
Figure 2 shows the 30-day mortality depending on the DAS.
Table 5: How to calculate 30-day mortality after endovascular repair or open surgery for pa-
tients with ruptured AAA
AAA = abdominal aortic aneurysm, CT = computed tomography, DAS = Dutch Aneurysm Score
* The definition for hemodynamic stability differed across the hospitals (see “Methods” section).
† Age in years.
‡ Shock was defined as a systolic blood pressure less than 80 millimeter Mercury.
§ Myocardial disease comprised previous myocardial infarction and/or angina pectoris.
|| Cerebrovascular disease included all previous cerebrovascular accidents and transient ischemic attacks.
# Renal failure referred to a preoperative creatinine value more of than 160 micromol per liter (i.e., 1.8 milligram per deciliter).
Example A 72-year old patient with a ruptured AAA, who is sufficiently hemodynamically stable to undergo CT-scan or angiography 
prior to the procedure, previously had a myocardial infarction, and has a preoperative creatinine value of more than 160 
micromol per liter.
Steps Formulas Endovascular repair Open surgery
1. Calculate DAS DAS = + 3 if hemodynamically unstable prior to the procedure* - 9 
for endovascular repair + age† + 17 for shock‡ + 7 for myocardial 
disease§ + 10 for cerebrovascular disease|| + 14 for renal disease#
DAS = + 0 – 9 + 72 + 
0 + 7 + 0 + 14 = 84
DAS = + 0 – 0 + 72 +  
0 + 7 + 0 + 14 = 93
2. Calculate linear  
 predictor
Linear predictor = – 4.76 + 0.051 * DAS Linear predictor = – 4.76 +  
0.051 * 84 = – 0.48
Linear predictor = – 4.76 +  
0.051 * 93 = – 0.017
3. Calculate 30-day  
 mortality
30-day mortality = 1 – (1 / (1+exp (linear predictor))) 30-day mortality = 1 –  
(1 / (1+exp (– 0.48))) = 0.38
30-day mortality = 1 –  
(1/ (1+exp (0.017))) = 0.50
Figure 2: 30-day mortality as a function of the Dutch Aneurysm Score 
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DISCUSSION
Policies for treatment of AAA have changed since the introduction of endovascular repair for 
patients with ruptured AAA. Patients who are hemodynamically stable receive a CT-scan or an-
giography prior to the procedure to assess anatomic eligibility for endovascular repair. Those 
who are too hemodynamically unstable to undergo imaging are immediately transported to the 
operating room for open surgery. Therefore, in this prospective multicenter study, we aimed to 
validate the GAS both in patients with ruptured AAA treated with open surgery and in those 
treated with endovascular repair. Furthermore, we updated the GAS to predict 30-day mortality 
after either endovascular repair or open surgery in patients with ruptured AAA. We found that 
the GAS showed limited discriminative ability in our patient population. In addition, we showed 
that, considering the included risk factors, 30-day mortality was always lower if patients with 
ruptured AAA were treated with endovascular repair as opposed to open surgery. 
The limited discriminative ability of the GAS may be due to the introduction of endovascular 
repair in patients with ruptured AAA. When the GAS was developed, open surgery was the only 
treatment for ruptured AAAs. The limited discriminative ability of the GAS suggests that factors 
not involved in the GAS influenced mortality after repair for ruptured AAA. In addition, in the 
evaluation of predictive values of the GAS, we found that patients with a high GAS would benefit 
less from endovascular repair. This is not consistent with previous findings, suggesting that pa-
tients at higher risk for peri-procedural cardiac complications would benefit more from endovas-
cular repair than those at lower risk (13). It should be noted, however, that confidence intervals 
surrounding the odds ratios were wide.
In the DAS, we added 2 new variables to the GAS variables: patients’ hemodynamic stability prior 
to the procedure and the type of procedure performed. It turned out that patients who were 
hemodynamic stable prior to the procedure had lower 30-day mortalities than those who were 
not. This may be due to selection criteria since hemodynamically stable patients are expected 
to have lower 30-day mortalities than those who are not hemodynamic stable and therefore 
were immediately transported to the operating room for open surgery (6). Similar to hemody-
namically stable patients, hemodynamically unstable patients might better undergo endovascu-
lar repair than open surgery if the anatomy allows. Therefore, it remains to be clarified whether 
hemodynamically unstable patients should undergo imaging prior to the procedure, although 
most patients appear to be sufficiently stable to do so (17).
Furthermore, the DAS showed that patients who underwent endovascular repair had lower 30-
day mortalities than those who underwent open surgery. Again, this may be due to selection 
criteria since all endovascular repair patients were by definition hemodynamically stable, while 
26% of open surgery patients were not. In addition, the interaction terms between GAS variables 
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and the therapeutic procedure performed were not associated with 30-day mortality. This sug-
gests that given the particular set of risk factors in our model, endovascular repair was always 
preferable with respect to 30-day mortality. 
Two studies that validated GAS in patients with ruptured AAA treated with open surgery 
reported better validity than our study (2, 3), and one study reported worse validity (4). It should 
be noted that these studies were performed in patients treated with open surgery, whereas in 
our study patients treated with open surgery as well as patients treated with endovascular repair 
were included. 
Our study had several limitations. The definitions of risk factors were slightly different from the 
original GAS. In addition, since the intent is for the model to be predictive, the GAS only included 
patient characteristics that can be known upon patients’ presentation to the hospital or shortly 
thereafter. Consequently, we did not collect data on the AAA anatomy, such as neck length, neck 
diameter, and neck angulation. Furthermore, our prediction rule is not based on a randomized 
controlled trial, and the selection for endovascular repair was based on patients’ hemodynamic 
condition and AAA eligibility for endovascular repair. Therefore, selection bias may have affected 
our results in favor of endovascular repair. The data we used, however, were based on patients 
who were seen consecutively, and our study represents current clinical practice. Fourth, we had 
a small sample; therefore, lack of statistical power may have affected our results.
The treatment protocols between the participating hospitals were slightly different. The crite-
ria for patients being hemodynamically (un)stable differed across the hospitals. In addition, the 
types of endografts used were not the same in all hospitals. As a result, different anatomic criteria 
were applied across the participating hospitals. It should be noted that in practice, physicians 
tend to apply more lenient criteria for endovascular repair in case of severe comorbidity in or-
der to avoid open surgery. In order to implement a more uniform treatment policy for patients 
with ruptured AAAs, similar protocols are needed in the different hospitals. In addition, these 
protocols enable more precise comparison of endovascular repair with open surgery across the 
different hospitals.
We recommend ongoing prospective observational and randomized controlled trials in patients 
with ruptured AAA. Prospective observational studies reflect daily practice and changes in treat-
ment policy over time (18, 19). This is of particular interest in this group of patients, since new 
types of endografts, which allow for more lenient anatomic criteria, are rapidly becoming avail-
able. Randomized controlled trials are needed in order to assess associations between risk fac-
tors, the procedure performed, and 30-day mortality, and to avoid selection bias. Furthermore, 
future studies should investigate which patients should go immediately to the operating room 
for open surgery and which patients should undergo imaging prior to the therapeutic procedure 
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to determine anatomic eligibility for endovascular repair. In addition, since patient populations 
may change over time, the development of a prediction tool is an ongoing process; therefore, we 
encourage further validation and updating of our prediction rule. 
In conclusion, we showed limited discriminative ability of the GAS in patients with ruptured AAAs 
to be treated with endovascular repair or open surgery. The GAS was updated into the DAS, by 
adding patients’ hemodynamic stability prior to the procedure and the type of procedure per-
formed, which predicts 30-day mortality for patients with ruptured AAA to be treated with either 
endovascular repair or open surgery. 
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ABSTRACT
Purpose: To retrospectively assess in-hospital costs and costs of 1-year follow-up of endovascular 
aneurysm repair and conventional open surgery in patients with an acute infrarenal abdominal 
aortic aneurysm (AAA), using the resource utilization approach.
Materials and methods: Institutional Review Board approval was obtained and informed con-
sent was waived because we analyzed only patient data documented as part of routine clinical 
care collected from the medical records. In-hospital costs for all consecutive patients undergoing 
endovascular (n = 32) or open surgical repair (n = 35) of acute infrarenal AAA from January 1, 
2001 until December 31, 2004 were assessed using the resource utilization approach. Patients 
who did not undergo a computed tomography (CT) scan before the procedure were excluded 
from the analysis. Costs of 1-year follow-up were complete for 30 patients who underwent endo-
vascular repair and 34 patients who underwent open surgery. Costs were assessed from a health-
care perspective. Mean costs were calculated for each treatment group and compared using the 
Mann-Whitney U-test, α = 0.05. In uni- and multivariable analyses, we investigated the influence 
of clinical variables on the total in-hospital costs. Costs were expressed in 2003 Euros.
Results: Sex (61 male, 6 female), age (mean 72.0), and comorbidity did not differ between the 
treatment groups (p > 0.05). The mean total in-hospital costs were lower for endovascular repair 
compared to open surgical repair (€ 20,767 and € 35,470, respectively; p = 0.004). The total costs 
including one-year follow-up were € 23,588 versus € 36,448 for patients who underwent endo-
vascular repair and open surgical repair, respectively (p = 0.05). In multivariable analysis, compli-
cations had a significant influence on total in-hospital costs (2.27 times higher costs).
Conclusion: Total in-hospital costs and total costs including 1-year follow-up were lower for pa-
tients with an acute AAA who underwent endovascular repair compared to open surgical repair. 
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INTRODUCTION
The exponential growth in technological developments in medicine lead to new treatment 
options for patients. Especially in the field of radiology and vascular surgery numerous improve-
ments have been made in the past few decades. One of the new treatment options is endo-
vascular repair in patients with an acute infrarenal Abdominal Aortic Aneurysm (AAA). Several 
studies have reported on the effectiveness of endovascular repair in patients with acute symp-
tomatic or ruptured AAAs (1-7). The results demonstrated a reduction in mortality and morbidity 
rates compared with open surgery. 
Endovascular repair performed electively in patients with an asymptomatic infrarenal AAA was 
demonstrated to cost more than open surgery (8). In patients with acute AAAs, costs have previ-
ously been assessed in patients subjected to open surgery. The results of these studies, however, 
were quite different from each other reporting total in-hospital costs that varied from $ 13,396 
to $ 126,305 (9-15). The methods of these studies varied and were based on small sample sizes. 
To our knowledge no study has been published yet that reported total in-hospital costs for the 
treatment of acute infrarenal AAA by endovascular repair and comparing these with open sur-
gery in acute AAA patients. 
Furthermore, most studies so far have only taken immediate costs associated with the procedure 
into account. Costs of follow-up should, however, be considered, as fairly intensive surveillance 
is needed in patients treated with endovascular aneurysm repair, whereas patients treated with 
open surgery do not require such an intense surveillance during follow-up (16-20). In addition, 
costs associated with additional procedures due to failures or complications should be consid-
ered. Patients treated with open surgery are expected to undergo more procedures for severe 
complications immediately following the procedure whereas endovascular treated patients are 
expected to undergo more procedures for graft failures or complications that may occur later 
in follow-up. Thus, in order to evaluate the incurred costs of both procedures, it is important to 
calculate both in-hospital costs and costs during follow-up after the procedure. The objective of 
our study, therefore, was to retrospectively assess in-hospital costs and costs of 1-year follow-up 
of endovascular aneurysm repair and conventional open surgery in patients with an acute infra-
renal AAA, using the resource utilization approach (21). 
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MATERIALS AND METHODS
Patients and protocol
The medical records of all consecutive patients with an acute infrarenal AAA who presented to 
our academic hospital between January 1, 2001 and December 31, 2004 were reviewed. An acute 
infrarenal AAA was defined as either an acute symptomatic infrarenal AAA or an acute ruptured 
infrarenal AAA. We limited our study to admissions beginning in 2001 since endovascular re-
pair of acute abdominal aneurysms became routine practice in our hospital from that time. All 
patients with an acute infrarenal AAA were retrieved from the medical registry using operation 
codes. These codes are used for administration purposes and valid for our institution specifically. 
The data were retrospectively obtained from a computerized database of the hospital and the 
medical records of all these patients were analyzed. Readmissions were obtained from patients’ 
medical records and the computerized database of our hospital or the hospital they were read-
mitted to. Institutional Review Board approval was obtained and informed consent was waived 
because we analyzed only patient data documented as part of routine clinical care and collected 
from the medical records.   
Upon the patient’s admission to the hospital, an abdominal ultrasound and/or an abdominal CT-
scan was performed. Patients were diagnosed with an acute infrarenal symptomatic or ruptured 
AAA by the vascular surgeon and the interventional radiologist who were on call. The four vascu-
lar surgeons involved had 3, 4, 4, and 5 years of experience in endovascular AAA repair and 4, 10, 
30, and 35 years of experience in open AAA repair, respectively, as of 2001. The two interventional 
radiologists involved had 3 and 5 years of experience in endovascular AAA repair, respectively, as 
of 2001. Depending on the morphologic anatomy of the aneurysm (e.g., proximal neck shorter 
than 15 millimeters, angulation more than 90º), the vascular surgeon and the interventional radi-
ologist decided whether to perform endovascular repair or open surgery. Six patients did not re-
ceive a CT-scan due to a hemodynamically instable condition. These patients went immediately 
to the operating room for open surgery and were excluded from the analyses.
The endovascular as well as the open procedure were performed by using commercially avail-
able grafts (Cook Zenith, Gore Excluder, Vascutek Sulzer/Terumo). The team that performed open 
surgery included one vascular surgeon (4 involved, average 4 years of experience in endovascu-
lar AAA repair and 20 years of experience in open AAA repair, as of 2001), one surgery fellow (3 
involved, average 1 year of experience in endovascular AAA repair and 3 years of experience in 
open AAA repair), one anesthesiologist (6 involved, average 15 years of experience), one anes-
thesiology fellow (2 involved, average 2 years of experience), and two operating room nurses (10 
involved, 10 years of experience). When an endovascular procedure was performed, the same 
team was present plus one radiologist (2 involved, average 4 years of experience) and one radio-
logic technologist (4 involved, average 4 years of experience). 
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In our study period, 100 patients presented at the Vascular Unit with an acute AAA (Figure 1). 
Twenty-four patients with a juxtarenal AAA were excluded from the analyses, because these 
patients were not eligible for endovascular repair. Two patients had an AAA of unknown ori-
gin. One patient was lost to follow-up because this patient was transported to another hospital 
immediately after open surgery for acute AAA. As mentioned above six patients who were too 
unstable did not undergo CT-scanning prior to the procedure. To make the patients in the endo-
vascular and open surgical treatment group more comparable, these 33 patients were excluded 
from the analyses. Therefore, in our analyses we included 67 patients with an acute infrarenal 
AAA, of whom 32 underwent endovascular repair and 35 open surgery (Figure 1).
Costs
Direct hospital costs of all patients were assessed using the resource utilization approach by 
multiplying resource utilization with the cost per unit of resource (21, 22). We assessed the in- 
hospital costs and costs during 1-year follow-up from a health care perspective. 
Figure 1: Flowchart of patients with an acute Abdominal Aortic Aneurysm included in the 
analyses.
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Total in-hospital costs were determined by preoperative costs, costs of the procedure, costs of 
the intensive care unit (ICU) and ward, costs of the postoperative diagnostic tests, costs of post-
operative blood products, and costs of additional procedures. All costs included personnel costs, 
use of equipment, use of material, investment during use, maintenance, administration and other 
overhead costs. To calculate the actual costs of the diagnostic tests and procedure related items, 
we retrieved data from the Financial Unit of the Department of Radiology, the Financial Unit 
of the operating rooms, and the Financial Unit of Surgery. To increase generalizability among 
hospitals, we used costs reported in the “Dutch manual for cost-analysis in health care” (23) to 
assess the costs, for example, of the ward (€ 476 per day) and the ICU (€ 1,684 per day). Finally, in 
the absence of actual costs for tests and procedures due to failures and complications, charges 
were obtained from the ‘National Health Tariffs Authority’. In the Netherlands, these charges are 
estimated based on actual costs. Therefore, it was not necessary to adjust these charges with a 
cost-to-charge ratio.
 
Preoperative costs included use of the emergency room and radiological diagnostic tests per-
formed prior to the procedure, such as an abdominal ultrasound or CT-scan. Procedure costs of 
the endovascular and surgical treatment included costs for use of the operating room, anesthe-
siology, personnel, materials such as grafts, catheters, sterilized gauzes, needles, and blood prod-
ucts. Costs of the ward and ICU stay included costs of physician consultations, nurses, materials, 
and medication. Costs of postoperative diagnostic tests included CT-angiography, abdominal 
ultrasound, sigmoidoscopy, and bronchoscopy. Costs of postoperative blood products included 
use of packaged cells, fresh frozen plasma, and platelets. Costs of additional procedures included 
procedures such as tracheostomy, Hartmann-procedure, and surgical evacuation of an access 
site hematoma or infection due to the treatment of the acute AAA.
For 64 patients 1-year follow-up was completed. Thirty patients underwent endovascular repair, 
34 patients were treated by open surgery. For three patients, of whom two underwent endovas-
cular repair and one open surgery, we could not complete the full 1-year follow-up because they 
were treated for an acute AAA less than a year ago. These patients were excluded from the cal-
culations of total costs including 1-year follow-up even if they died peri-procedurally. Following 
the procedure, during the 1-year follow-up, three patients treated with endovascular repair died 
due to non-aneurysm related causes, namely pulmonary infection, heart failure, and malignancy. 
Costs of 1-year follow-up included scheduled follow-up physician visits and costs of diagnostic 
tests. For patients who underwent endovascular repair, physician visits and CT-scans were sched-
uled 3, 6, and 12 months after the initial procedure. For patients who underwent open surgery, 
physician visits were only scheduled on clinical indication. Also, costs of readmissions due to 
failures and complications of the treatment of the acute AAA were assessed. These costs included 
costs of diagnostic tests, ward stay, and procedures during readmission and were determined as 
described above. All costs were calculated in 2003 Euros.
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Data and statistical analysis
Patient and lesion characteristics between the patients who underwent endovascular and 
open repair were compared using the Student t-test, Mann-Whitney U-test, χ2-test and Fisher’s 
Exact Test (two-sided, α = 0.05). For each patient, we calculated the total in-hospital costs and the 
costs of 1-year follow-up. In 7 patients (10%) we missed a few items related to the preoperative 
costs such as use of the abdominal ultrasound; these missing values were imputed using the 
mean-imputation method (24). Data to assess all other cost items were complete. Consistent 
with intention-to-treat analyses, the mean in-hospital costs were calculated by taking all patients 
(n = 67) into account, including patients who died. Costs during follow-up were calculated taking 
all patients into account (n = 64). In order to increase the precision of the 95% confidence interval 
of the mean, we used the bootstrap resample method. The costs of patients who received endo-
vascular repair versus open surgery were compared using the Mann-Whitney U-test (two-sided, 
α = 0.05). 
In univariable analyses, we tested which variables had a significant influence on the natural loga-
rithm of the total in-hospital costs (α = 0.10). Because the distributions of the costs were skewed, 
we used the natural logarithm. The variables tested were age, sex, comorbidity (i.e., cardiovascu-
lar or respiratory disease), ruptured versus symptomatic AAA, open versus endovascular repair, 
in-hospital complications due to the treatment of the acute AAA, and in-hospital death. We de-
fined in-hospital complications as myocardial infarction, respiratory insufficiency, pneumonia, 
renal failure, ischemia of the sigmoid, sepsis, abdominal haematoma, and urinary tract infection. 
The significant variables (α = 0.10) from the univariable analyses were included in a multivariable 
regression analysis. On the basis of this multivariable model, the mean difference in total in- 
hospital costs for endovascular versus open surgery was calculated using the formula: 
ΔTotal in-hospital costs = (Total in-hospital costs)Open surgery– (Total in-hospital costs)Endovascular repair = 
e(C+ βr*Fr + βo*Fo + βc*Fc )–e(C+ βr*Fr + βo*Fo + βc*Fc)
where, 
  C = constant
  βr = β ruptured versus symptomatic AAA
  Fr = fraction of patients who had a ruptured AAA
  βo = β open versus endovascular repair 
  Fo = fraction of patients who underwent open surgical repair
  βc = β complications 
  Fc = fraction of patients who had a complication
Because studies showed that the clinical outcome and anatomic suitability to treat patients with 
an acute AAA with an endovascular approach may be different for symptomatic and ruptured 
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AAA (25, 26), subgroup analysis for in-hospital costs in patients with a ruptured AAA was per-
formed. 
Analyses were performed using Microsoft Excel 2000 (Microsoft Corporation, Redmond, WA), 
SPSS for Windows Version 11.0.1 (SPSS Inc., Chicago, Il), and S-Plus Version 6.0 Professional Re-
lease 1 (Insightful Corporation, Seattle, WA). 
RESULTS
In our study group, we included 61 (91%) men and 6 (9%) women. Baseline patient demographics 
were not different between the two treatment groups (Table 1). 
Fourteen (44%) of the 32 patients who underwent endovascular repair had a ruptured AAA, 
whereas 25 (71%) of the 35 patients who underwent open surgery had a ruptured AAA 
Table 1: Patient demographics and admissions 
SD = standard deviation, AAA = abdominal aortic aneurysm, ICU = intensive care unit
* Comorbidity = cardiovascular or respiratory disease; comorbidity data was not available for one patient who underwent open 
surgical repair, which changed the denominator to 34 patients for open surgical repair.
† Four patients were not admitted to the ICU as they died intraoperatively. 
‡ Follow-up data were available for 30 endovascular repair treated patients and 34 open surgical treated patients; readmissions 
included: embolisation endoleak, leakage of the wound, back pain suspected for aneurysm related problems, endovascular repair 
of an aneurysm of the femoral artery, and anal blood loss.
Endovascular repair  
n = 32
Open surgical repair 
n = 35
P-value
Male 28 (88%) 33 (94%) 0.29
Mean age (SD) 71.3 (9.9) 72.6 (10.0) 0.57
Comorbidity* 22 (69%) 23 (68%) 0.63
Ruptured AAA 14 (44%) 25 (71%) 0.02
General anesthesia 16 (50%) 35 (100%) < 0.001
ICU admission 15 (47%) 31 (89%)† < 0.001
In-hospital complications 11 (34%) 19 (54%) 0.14
In-hospital mortality 4 (13%) 9 (26%) 0.22
Readmissions in follow-up‡ 2 (7%) 4 (12%) 0.68
Admission time: mean (SD), median
   Duration procedure in minutes 169 (53), 157 239 (70), 230 < 0.001
   Postoperative days in the ICU 3.0 (8.0), 0.15 9.4 (14.4), 1.9 < 0.001
   Postoperative days on the ward 7.7 (10.3), 6.0 12.7 (14.9), 9.0 0.07
   Postoperative days in hospital 10.7 (15.7), 6.5 22.1 (24.3), 14.8 0.003
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(p = 0.02). Fifteen (47%) of the 32 patients who underwent endovascular repair were admitted to 
the ICU, whereas 31 (89%) of the 35 patients who underwent open surgery were admitted to the 
ICU. Frequencies of in-hospital complications and in-hospital mortality were lower in the endo-
vascular group (34% versus 54% (p = 0.14) and 13% versus 26% (p = 0.22) for endovascular and 
open repair, respectively). The mean postoperative stay in the ICU was lower after endovascular 
than after open repair (3.0 days vs. 9.4 days, respectively; p < 0.001). None of the patients who 
were treated with an endovascular repair underwent conversion to open surgery.
In-hospital costs
The mean total in-hospital costs were lower in patients who underwent endovascular re-
pair compared to patients who underwent open surgery (€ 20,767 and € 35,470, respectively; 
p = 0.004; Table 2).
The distribution of these costs for both treatments was skewed to the right, although the range 
of total in-hospital costs of patients who underwent endovascular repair was smaller than of 
patients who underwent open surgery (Figure 2a and 2b). 
More specifically, preoperative costs were higher in patients who underwent open surgery (Table 
2). This was mainly because these patients visited the emergency room (as opposed to being 
Table 2: Mean in-hospital costs of acute AAA repair 
AAA = abdominal aortic aneurysm, ICU = intensive care unit
* In 2003 Euros
Endovascular repair (n = 32) 
Costs (€)* (min-max)
Open surgical repair (n = 35) 
Costs (€)* (min-max)
P-value
Preoperative costs 386 (279-455) 411 (349-492) 0.10
Costs procedure 9829 (2863-16931) 9181 (1222-24484) 0.14
Costs ICU 5048 (0-57168) 15822 (0-91883) < 0.001
Costs ward 3674 (0-24752) 6052 (0-36176) 0.07
Costs postoperative 
diagnostic tests:
 - Radiology Department 393 (0-1673) 520 (0-1853) 0.65
 - Other Departments 957 (68-7969) 2275 (0-11767) < 0.001
Costs postoperative blood 
products
141 (0-1432) 684 (0-7728) 0.03
Costs additional procedures 338 (0-6593) 525 (0-5467) 0.17
Total in-hospital costs 20767 (6644-78983) 35470 (1674-131536) 0.004
95%-confidence interval 15479-29355 25933-48245
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Figure 2a: Distribution of total in-hospital costs of endovascular repair in patients treated for 
acute Abdominal Aortic Aneurysms
Figure 2b: Distribution of total in-hospital costs of open surgery in patients treated for acute 
Abdominal Aortic Aneurysms 
COST ANALYSIS WITH 1-YEAR FOLLOW-UP
77
admitted through the outpatient clinic) more often than patients who underwent endovascular 
repair. The largest difference within the hospital costs between the treatment groups was found 
in the costs of the ICU (€ 5,048 versus € 15,822 for endovascular repair and open surgery, respec-
tively; p < 0.001). 
Procedure costs
The mean total procedure costs were not different between the two treatment groups (€ 9,829 
versus € 9,181 for endovascular repair and open surgery, respectively; p = 0.14; Table 3).
All procedural cost items were lower for endovascular repair (p < 0.001), except for the material 
costs; this was mainly due to the price of the stent graft itself, which varied between € 3,515 and 
€ 10,944 (mean € 5,281), whereas the cost of a graft for open surgery was less than € 1,000.
Follow-up costs
The total costs during 1-year follow-up were higher for endovascular repair compared to open 
surgery (€ 2,012 versus € 694; p = 0.003; Table 4).
Costs of diagnostic tests performed by the Radiology Department were higher for endovascular 
repair. Total costs including in-hospital costs and 1-year follow-up were lower for endovascular 
repair than for open surgery (€ 23,588 versus € 36,448; p = 0.05).
Analyses of covariates
Univariable analyses showed no significant associations between the total in-hospital costs and 
age, sex, comorbidity, and in-hospital death. However, ruptured versus symptomatic AAA, open 
versus endovascular repair, and complications were associated with increased total in-hospital 
costs (Table 5).
Table 3: Mean procedure costs of acute AAA repair 
AAA = abdominal aortic aneurysm
* In 2003 Euros
Endovascular repair (n = 32) 
Costs (€)* (min-max)
Open surgical repair (n = 35) 
Costs (€)* (min-max)
P-value
Operating room 1492 (699-2700) 2118 (354-3842) < 0.001
Anesthesiology 1578 (740-2856) 2240 (375-4063) < 0.001
Personnel 721 (338-1304) 1023 (171-1856) < 0.001
Material 5617 (501-11446) 734 (322-932) < 0.001
Blood products 421 (0-2428) 3066 (0-14099) < 0.001
Total procedure costs 9829 (2863-16931) 9181 (1222-24484) 0.14
Chapter 5
78
Table 4: Mean costs during 1-year follow-up in patients treated for acute AAA repair 
AAA = abdominal aortic aneurysm
* In 2003 Euros
† Readmissions included: embolisation endoleak, leakage of the wound, back pain suspected for aneurysm related problems, 
endovascular repair of an aneurysm of the femoral artery, and anal blood loss.
Endovascular repair (n = 30) 
Costs (€)* (min-max)
Open surgical repair (n = 34) 
Costs (€)* (min-max)
P-value
Visits 287 (0-600) 276 (0-800) 0.52
Costs diagnostic tests:
  - Radiology Department 338 (0-840) 27 (0-210) <0.001
 - Other Departments 11 (0-107) 22 (0-103) 0.13
Readmissions: costs procedures† 82 (0-2465) 36 (0-1207) 0.91
Readmissions: costs diagnostic tests: 
 - Radiology Department 7 (0-210) 31 (0-587) 0.35
 - Other Departments 18 (0-525) 36 (0-1010) 0.23
Readmissions: costs ward 1269 (0-23800) 266 (0-4284) 0.56
Total costs during 1-year follow-up 2012 (0-24325) 694 (0-6610) 0.003
95% confidence interval 676-4987 393-1384
Total costs including 1-year follow-up 23588 (8770-79293) 36448 (1674-132136) 0.05
95% confidence interval 18187-33691 27693-51508
Table 5: Univariable analyses on the natural logarithm of total in-hospital costs of acute AAA 
repair
AAA = abdominal aortic aneurysm
* These numbers represent the relative costs due to the specific variable and were retrieved by transforming the β-coefficient using 
the formula eβ with β=β variable
† These numbers represent the incremental costs for the index versus the reference group and were calculated using the formula 
eC+β-eC with C=constant and β=β variable
‡ Comorbidity = cardiovascular or respiratory disease
β- coefficient Relative cost ratio* Incremental costs† Standard error P-value
Age 0.002 - - 0.01 0.85
Sex (female versus male) -0.43 0.65  - 7318 0.33 0.20
Comorbidity‡ 0.05 1.05  948 0.09 0.59
Ruptured versus symptomatic 
AAA
0.50 1.64  9750 0.19 0.01
Open versus endovascular repair 0.42 1.51  8393 0.19 0.03
Complications 0.92 2.50  20218 0.16 < 0.001
In-hospital death - 0.13 0.88  - 2516 0.24 0.60
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In the multivariable regression procedure, the variables ruptured versus symptomatic AAA and 
open versus endovascular repair were not significantly associated with costs (Table 6).
The variable complications was associated with the total in-hospital costs, that is patients with 
complications incurred 2.27 times more total in-hospital costs than patients with no complica-
tions. On the basis of this model, the mean difference in total in-hospital costs for endovascular 
versus open repair, with adjustment for ruptured versus symptomatic AAA and complications, 
was € 3,903, in favor of endovascular repair. 
Ruptured AAAs
Regarding our subgroup analysis in patients with ruptured AAAs (Table 7), the mean total in-
hospital costs for patients with a ruptured infrarenal AAA were lower for those who underwent 
endovascular repair (€ 28,163 versus € 42,609; p = 0.06).
DISCUSSION
Endovascular repair has become an important and increasingly performed alternative to open 
surgery in patients with an acute AAA. The principal finding of our study was that the total in-
hospital costs for endovascular repair were lower than for open surgery. In addition, total costs 
including the initial hospital costs and costs of 1-year follow-up were also lower for endovascular 
repair.
The most important cause for the difference in total in-hospital costs between endovascular and 
open repair were the costs of the ICU. Approximately half of the patients (15/32, 47%) who un-
derwent endovascular repair were admitted to the ICU, whereas 31 (89%) of the 35 patients who 
underwent open surgery were admitted to the ICU. The length of stay in the ICU also played an 
Table 6: Multivariable regression analysis on the natural logarithm of total in-hospital costs of 
acute AAA repair
AAA = abdominal aortic aneurysm 
* These numbers represent the relative costs due to the specific variable and were retrieved by transforming the β-coefficient using 
the formula eβ with β=β variable
β-coefficient Relative cost ratio* Standard error P-value
Constant 9.33 - 0.14 < 0.001
Ruptured versus symptomatic AAA 0.21 1.24 0.17 0.20
Open versus endovascular repair 0.19 1.21 0.16 0.24
Complications 0.82 2.27 0.16 < 0.001
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important role, which was shorter for patients treated with endovascular repair than for patients 
who underwent open surgery (3.0 days vs. 9.4 days, respectively; p < 0.001).
Another finding of our study was that mean total costs of the procedures itself did not dif-
fer. However, the component costs were quite different between the procedures. Costs of the 
operating room, anesthesiology and personnel were higher in patients who underwent open 
surgery, caused by the longer procedure time in these patients. The higher costs of materials in 
patients who underwent endovascular repair were mainly caused by the use of expensive endo-
grafts. The high costs of blood products in patients who underwent open surgery, was caused 
by the large amount of blood loss in these patients. These differences cancelled out, leading to 
similar total costs of the procedures.
Furthermore, our study showed that costs of 1-year follow-up were higher for endovascular re-
pair compared to open surgery. This was to be expected since regular CT-scans were performed 
to identify possible endoleaks, graft migration or other complications related to the endovascu-
lar repair (16, 19, 20). In addition, patients who undergo endovascular repair probably will have 
more complications in the long run due to these graft related failures. 
Table 7: Mean in-hospital costs and length of hospitalstay for ruptured AAA
ICU = intensive care unit, SD = standard deviation
* In 2003 Euros
Endovascular repair (n = 14) 
Costs (€)* (min-max)
Open surgical repair (n = 25) 
Costs (€)* (min-max)
P-value
Preoperative costs 373 (279-418) 414 (349-492) 0.01
Costs procedure 9606 (2863-16931) 10048 (1222-24484) 0.81
Costs ICU 10786 (0-57168) 20853 (0-91883) 0.15
Costs ward 4624 (0-24752) 6226 (0-36176) 0.53
Costs postoperative diagnostic tests:
 - Radiology Department 509 (0-1673) 603 (0-1853) 0.85
 - Other Departments 1733 (68-7969) 2913 (0-11767) 0.09
Costs postoperative blood products 296 (0-1432) 943 (0-7728) 0.23
Costs additional procedures 237 (0-1671) 609 (0-5467) 0.52
Total in-hospital costs 28163 (6644-78983) 42609 (1674-131536) 0.06
95%-confidence interval 17890-46565 29479-60592
Admission time mean (SD), median
Postoperative days on ICU 6.4 (11.3), 0.9 12.4 (16.1), 5.5 0.14
Postoperative days on ward 9.7 (14.6), 4.0 13.1 (17.3), 9.0 0.53
Postoperative days in hospital 16.1 (22.4), 6.8 25.5 (28.0), 14.8 0.19
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Our univariable analyses showed a significant effect on total in-hospital costs of three variables: 
ruptured versus symptomatic AAA, open versus endovascular repair, and complications. When 
the three significant variables were included in a multivariable analysis, however, only compli-
cations was significant. This suggests that the demonstrated association between the variable 
ruptured versus symptomatic AAA and the total costs and the association between the type of 
repair and the total costs is explained by whether complications occurred. The difference in total 
in-hospital costs between the two treatments derived from the multivariable analysis, should 
be interpreted with caution, because the model had an R2 of 0.39, meaning that only 39% of the 
variation was explained by the model. 
In other studies, that determined the total in-hospital costs of open surgery in patients with rup-
tured AAAs, the results were quite different than our results (9-15). The most important reason 
for this was the large variation in the average length of stay in the ICU and on the ward reported. 
Furthermore, a limitation of these studies was the relatively small sample sizes compared to our 
study. Studies in which the total in-hospital costs for elective endovascular repair and open sur-
gery were assessed in patients with asymptomatic AAAs showed that costs of both treatment 
options were lower than the costs assessed in our study in patients with an acute AAA. This was 
as expected due to the shorter stay in the hospital, especially in the ICU, of patients who under-
went elective aneurysm repair (8, 12).
Our study has several limitations. The main problem was that the data were not based on a 
randomized controlled trial; therefore selection bias may be present. Also the sample size was 
relatively small and the follow-up was limited to 1 year. The small sample size made it hard to 
distinguish between statistically significant and insignificant findings. Therefore, we reported the 
p-values so that the reader can determine whether a finding is significant or not. In our cost com-
parison of endovascular and open repair in acute infrarenal AAA patients, we did not adjust for 
the indication of endovascular versus open surgical repair (i.e., anatomy of the aneurysm) in the 
included patients because this data was unfortunately not well documented (27). We did, how-
ever, limit the analyses to patients that were potentially eligible for either endovascular or open 
surgery and in whom selection of the type of repair was determined by anatomic morphologic 
considerations. Patients with an AAA with a proximal aneurysm neck shorter than 15 millimeter 
or an angulation of more than 90º were not considered suitable for endovascular repair. There-
fore, it remains unclear whether the difference in costs occurred due to the procedure performed 
or to the anatomy of the aneurysm.
Another limitation was that substantially more patients with ruptured AAAs received open sur-
gery. Therefore, we performed a subgroup analysis in patients with a ruptured AAA. Although 
mean total in-hospital costs for these patients did not differ, open surgery was at least € 14,000 
more expensive than endovascular repair. It may be possible that we did not demonstrate sta-
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tistical significance because of the large range in total in-hospital costs and the limited number 
of patients. 
Another limitation of our study is the possible limited generalizability of the results to other 
countries. We used unit costs from Dutch guidelines and hospitals. However, our results may be 
generalized to other countries by using methods like regression techniques and Markov deci-
sion models (21, 28, 29). In these models, differences in costs of medical treatments between 
countries due to factors like demography, epidemiology, culture, applicability of health care, dif-
ferences in medical practice, difference in resource use, funding of health care, and absolute and 
relative price differences can be taken into account (21, 28, 29). Furthermore, a limitation was 
that we used charges for tests and procedures performed due to failures and complications. In 
the Netherlands, however, these charges are estimations of the actual costs and therefore very 
similar. Furthermore, these charges accounted for less than 10% of the total in-hospital costs, 
which is considered acceptable in a cost accounting study (23). 
To decide whether patients with an acute AAA, who are eligible for endovascular repair, should 
preferably be treated with this procedure, costs as well as effects should be taken into account. 
To deal with the limitations of this study, namely the non-randomization, small sample size, and 
limited follow-up, more research in this area should be considered. 
In conclusion, total costs including in-hospital costs and 1-year follow-up in acute infrarenal AAA 
patients were lower for endovascular repair than for open surgery.
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ABSTRACT
Purpose: To evaluate the cost-effectiveness of endovascular repair versus open surgery in 
the treatment of a ruptured abdominal aortic aneurysm (AAA) and to investigate whether 
performing further research to obtain additional information is justified. 
Materials and methods: A Markov decision model was developed to evaluate long-term sur-
vival, quality-adjusted life years (QALYs), and lifetime costs for a hypothetical cohort of patients 
with ruptured AAA managed with endovascular repair or open surgery. Clinical effectiveness 
data were derived from a prospective multicenter study and from the literature. Cost data were 
derived from hospital databases and the literature. Probabilistic sensitivity analyses were per-
formed on uncertain model parameters. Value of information analysis was performed to estimate 
the benefit of future clinical cost-effectiveness research. 
Results: Quality-adjusted life expectancy was higher for endovascular repair than for open 
surgery (5.42 versus 4.85 QALY), and lifetime costs were lower for endovascular repair than for 
open surgery ($ 49,344 versus $ 50,765). This means that endovascular repair was superior to 
open surgery. In sensitivity analysis, the cost-effectiveness was influenced by short-term (i.e., 
30-day) complications and mortality after endovascular repair. The value of information analysis 
indicated that future cost-effectiveness research in patients with ruptured AAA is justified and 
should concentrate on short-term costs and clinical effectiveness. 
Conclusion: Our results suggest that endovascular repair yielded more QALYs and was also 
associated with lower lifetime costs compared with open surgery in patients with ruptured AAA. 
In addition, further research is justified and should concentrate on short-term costs and clinical 
effectiveness.
 
COST-EFFECTIVENESS AND VALUE OF INFORMATION ANALYSIS
87
INTRODUCTION
Patients with a ruptured abdominal aortic aneurysm (AAA) who are hemodynamically stable 
upon presentation to the hospital are usually evaluated with a CT-scan to assess whether they 
are eligible for endovascular repair. If the AAA is anatomically suitable for endovascular repair 
the patient will be treated with this procedure, otherwise the patient will undergo open surgery 
(1, 2). 
Recently, however, no statistical significant difference in 30-day mortality between endovascular 
repair and open surgery in patients with a ruptured AAA was suggested, when adjusted for pa-
tients’ hemodynamic condition upon presentation to the hospital (3). In addition, after elective 
AAA repair, patients treated with endovascular repair had about twice the number of aneurysm-
related complications requiring intervention during follow-up compared with patients treated 
with open surgery (4). Furthermore, costs of endovascular repair compared with open surgery in 
patients with ruptured AAA tend to be lower in the short term, whereas they may be higher in 
the long run, due to more intensive surveillance and more reinterventions during follow-up (5). 
The first question is whether, from a health policy perspective, current available evidence justi-
fies today’s policy to treat patients with ruptured AAA with endovascular repair if anatomically 
suitable. The second question is whether additional information is required to inform the deci-
sion making process for patients with ruptured AAA in the future (6). Therefore, the objective 
of this study is to evaluate the cost-effectiveness of endovascular repair compared with open 
surgery in patients with ruptured AAA and to investigate whether performing future research to 
obtain additional information is justified.
MATERIALS AND METHODS
The model 
A Markov cycle tree was developed to model long-term clinical effectiveness and costs of 
patients treated for ruptured AAA (Figure 1) (7). 
All patients underwent a CT-scan prior to the procedure. The strategies compared were endo-
vascular repair and open surgery. During the endovascular procedure, patients died or survived. 
If patients survived, the initial aneurysm repair could fail or could be successful. In the event 
of a failure, patients were treated with additional endovascular techniques or were converted 
to open surgery. Postoperatively all patients were at risk of having complications. During open 
surgery, patients died or survived. If patients survived, the initial aneurysm repair could fail or 
could be successful. In the event of a failure, they were treated with additional open surgical 
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techniques. All patients were at risk of having complications. During follow-up, patients treated 
successfully with endovascular repair underwent CT-scans after 3, 6, and 12 months, and annu-
ally thereafter. Patients treated successfully with open surgery were not subjected to follow-up 
visits. Patients whose initial endovascular repair failed were treated with endovascular or open 
surgical techniques. Patients in whom the initial open surgery failed were treated with open sur-
gical techniques.
Procedures considered during follow-up after failure of endovascular repair were percutaneous 
procedures, such as coil embolisation of an endoleak, and conversions to open surgery (8, 9). 
Figure 1: Simplified decision tree of the endovascular repair branch. Complications refer to 
morbidity of the procedure; failure refers to long-term complications such as endoleak. 
* The structure of the open surgical branch was identical to the structure of the endovascular repair branch, except for the endovascu-
lar option after failure of the ruptured AAA repair.
■ = decision,       = Markov node, ● = uncertain events, ◄ = indicates the end of the cycle-tree and possible transition to another state in 
the next cycle, CT = computed tomography scan, EVR = endovascular repair, OSR = open surgery, AAA = abdominal aortic aneurysm. 
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Procedures considered during follow-up after failure of open surgery were open surgical proce-
dures. We assumed that, during follow-up, no more than two open surgical procedures were per-
formed after endovascular repair and open surgery. The model updated patients’ clinical status 
and costs monthly. 
The analyses were performed according to the recommendations of the Panel on Cost- 
Effectiveness in Health and Medicine and performed from the societal perspective. Both costs 
and effects were discounted at 3% per year (10-12).
Data sources and assumptions
Clinical effectiveness
Short-term (i.e., 30-day) clinical data were obtained from a meta-analysis in which endovascular 
repair was compared with open surgery in patients with ruptured AAA (3) and a prospective mul-
ticenter observational study (4A-study) in which 7 institutions from the Netherlands participated 
(Tables 1 and 2).
Data were combined using Bayesian evidence synthesis (13). Uncertainty in the parameters of 
the model was reflected in distributions of each model parameter (Tables 1 and 2) (13). In our 
prospective multicenter observational study, 164 patients were included. These patients were 
hemodynamically stable upon presentation to the hospital and underwent a CT-scan or angi-
ography to determine anatomic eligibility of the AAA for endovascular repair. If patients were 
anatomically suitable for endovascular repair, they were treated with this procedure (n = 58); oth-
erwise they were treated with open surgery (n = 106). Institutional Review Board approval was 
obtained and informed consent was waived due to the observational nature of the study (14). 
Long-term clinical effectiveness data were based on published literature, with a focus on meta-
analyses and large clinical studies (Tables 1 and 2). Long-term life expectancy was calculated on 
the basis of age- and sex-specific mortality rates from U.S. life tables of the general population 
(15). An excess mortality rate to adjust survival was used for all patients and subsequently for 
those who had complications (16-20). 
Our prospective multicenter observational study demonstrated that the most frequently report-
ed short-term complications were cardiac, pulmonary, renal, and cerebrovascular. These com-
plications had a long-term effect with decreased health related quality-of–life and costs were 
increased. Data on complications after endovascular repair that may occur after 1-month follow-
up were not available. We assumed that the probability to get aneurysm-related complications 
requiring intervention after 1-month follow-up was equal to the probability to get aneurysm- 
related complications requiring intervention in electively treated patients with AAA (21).
Chapter 6
90
Health-related quality of life
Since most patients are asymptomatic before rupture, quality of life weights before treat-
ment were equal to those in the general population (22). Short-term quality of life ad-
justments were approximated by reducing a person’s quality of life by 10% for the first 
month after endovascular repair and by 30% for the first two months after open surgery. In 
addition, quality of life was reduced by 5% during the day that a patient treated with endovas-
cular repair had to undergo scheduled CT-scan. Quality of life weights after recovery from treat-
Table 1: Model probability estimates 
AAA = abdominal aortic aneurysm
* Percutenous treatment 100%; open surgery 0%. (4A-study) 
† Percutenous treatment 88%; open surgery 12 %.
Parameter Base-case Distribution Range Reference
Short-term (30-day) 
  Mortality
     Endovascular repair 0.21 Beta 0.15-0.40 4A-study, (3)
     Open surgery 0.28 Beta 0.20-0.45 4A-study, (3)
 Technical failure requiring intervention
     Endovascular repair* 0.09 Beta 0.05-0.20 4A-study
   Open surgery 0.03 Beta 0.001-0.10 4A-study
 Procedure related complications
  Endovascular repair† 0.10 Beta 0.05-0.30 4A-study
  Open surgery† 0.17 Beta 0.10-0-35 4A-study
Long term (>30-days)
 Mortality
  Relative Risk due to ruptured AAA repair 2 Lognormal 1-4 (16)
  Relative Risk of mortality due to myocardial infarction
   First year 4 Lognormal 3-6 (17)
   Follow-up (per year) 2 Lognormal 1-3 (17)
  Relative Risk of mortality due to pulmonary complications 4 Lognormal 2-7 (18)
  Relative Risk of mortality due to renal disease 4 Lognormal 2-6 (19)
  Relative Risk of mortality due to stroke
   First year 4 Lognormal 2-6 (20)
   Follow-up (per year) 2 Lognormal 2-6 (20)
Annual aneurysm-related complication rates  
requiring intervention
 Endovascular repair† 0.09 Beta 0.05-0.20 (46)
 Open surgery 0.02 Beta 0.005-0.05 (47)
Discount rate 0.03 - 0.01-0.05 (10)
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ment were similar to those before treatment (23, 24). For patients with irreversible complications, 
long-term quality of life adjustments were made by multiplying each year of life, adjusted for 
age- and sex-specific values in the general population, by a coefficient that ranged from 0.61 to 
0.91 depending on the type of complication (Table 2) (25-27).
Cost data
Cost data included costs of procedures, morbidity, and imaging during follow-up (Table 2) (4, 5, 
28-32). Data on initial procedure costs and imaging during follow-up were derived from a ret-
rospective cost analysis on ruptured AAAs (5). Data on morbidity costs were derived from the 
literature with a focus on large clinical studies (4, 28-32). All costs were converted to year 2005 
U.S. dollars on the basis of the Medical Care Component of the Consumer Price Index (33). If costs 
were reported in Euros, they were converted into U.S. Dollars using a currency rate of 1 Euro = 
Table 2: Model costs and quality of life estimates 
Parameter Base-case Distribution Range Reference
Costs (U.S. $ 2005)
 Endovascular repair 38296 Lognormal 24327-63320 (5)
 Open surgery 57940 Lognormal 40086-82394 (5)
 Percutaneous treatment during follow-up 7284 Lognormal 3642-10926 (28)
 Relaparotomy during follow-up 19024 Lognormal 9512-28536 (4)
 Follow-up imaging 865 Lognormal 432-1297 (5)
 Annual costs of complications
  Non-fatal myocardial infarction
   First year 22778 Lognormal 11389-34167 (29)
   Follow-up (per year) 1541 Lognormal 770-2311 (29)
  Pulmonary complications 5929 Lognormal 2964-8893 (30)
  Renal disease, dialysis dependent
   First year 17772 Lognormal 8886-26658 (31)
   Follow-up (per year) 8445 Lognormal 5233-15698 (31)
  Stroke
   First year 35383 Lognormal 17692-53075 (32)
   Follow-up (per year) 13178 Lognormal 6589-19767 (32)
Quality of life reduction coefficients
 Non-fatal myocardial infarction 0.91 Uniform 0.81-0.98 (25)
 Pulmonary complications 0.91 Uniform 0.81-0.98 (26)
 Renal disease, dialysis dependent 0.68 Uniform 0.58-0.78 (26)
 Stroke 0.61 Uniform 0.51-0.71 (27)
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1.25 U.S. dollars (34). If in the literature the year in which costs were expressed was not reported, 
we assumed that they were expressed in the year prior to publication. 
Procedure costs included costs of preoperative care, costs of the procedure itself, cost of inten-
sive care unit stay, cost of regular ward stay, cost of diagnostic in-hospital tests, cost of blood 
products, and costs of additional procedures. Costs of follow-up imaging in patients treated with 
endovascular repair included hospital costs for imaging and physician costs. All of these items 
contain costs of personnel, use of equipment, use of material, investment during use, mainte-
nance, administration, and overhead. We assumed that costs of a (re)laparotomy during follow-
up due to failure of the initial procedure were equal to an elective repair of the AAA.
Patient time costs during hospital stay were calculated by multiplying the daily wage rate for all 
men ($ 144 per day) by the number of days spent in the hospital (33). The number of days spent 
in the hospital was based on the prospective multicenter observational study, described above, 
and was 13 days after endovascular repair and 18 days after open surgery. Patient time costs for 
follow-up imaging were calculated by multiplying the daily wage rate by 0.5.
Data analysis
In the base-case (i.e., initial) analysis, we evaluated a cohort of 70-year old males with ruptured 
AAA who underwent a CT-scan prior to the procedure (i.e., the decision to treat the patients with 
endovascular repair or open surgery was based on the AAA anatomy and not on the patients’ 
hemodynamic condition). Quality-adjusted life years (QALYs), lifetime costs, and net health ben-
efits (NHB) were calculated for these patients. The NHB was calculated using the formula: 
NHBprocedure = Eprocedure – ((Cprocedure) / WTP). Eprocedure = QALYs associated with procedure, Cprocedure = 
costs associated with procedure, and WTP = willingness to pay = $ 75,000. 
We performed sensitivity analyses on uncertain model parameters, such as 30-day mortality, 
complication rates, procedure costs, follow-up imaging costs, and health-related quality of life 
weights. Threshold analyses using net health benefit as outcome were performed to determine 
the value of the variables at which the optimal treatment strategy changed. We considered 
$ 75,000 per QALY gained the threshold WTP (35). 
Analyses were performed using TreeAge Pro 2006 (Boston, MA) and Microsoft Excel 2000 (Micro-
soft Corporation, Redmond, WA).
Value of information (VOI) analysis
VOI analysis estimates the difference between the expected value of a decision based on current 
available evidence and the expected value of a decision based on perfect information. This differ-
ence indicates the value of future research. For this analysis, costs and effects were transformed 
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into one composite outcome, net monetary benefits (NMB), which is the monetary equivalent 
of effectiveness (36). The NMB was calculated using the formula: NMB = WTP * Eprocedure – Cprocedure. 
WTP = willingness to pay = $ 75,000, Eprocedure = QALYs associated with procedure, and Cprocedure = 
costs associated with procedure. VOI analysis techniques were used to calculate the expected 
value of perfect information (EVPI) by performing 100,000 Monte Carlo simulations. The EVPI was 
defined as the difference between the expected value of the decision based on existing informa-
tion and the expected value of the decision based on perfect information. Next, the population 
EVPI was estimated, which was the total EVPI per patient multiplied by the total number of pa-
tients that would benefit from the decision over the lifetime of the technology. It was estimated 
that in The Netherlands about 200 patients with ruptured AAA are eligible for both endovascu-
lar repair or open surgical treatment annually and would therefore benefit from future research 
in this area (37). The lifetime of the technology was estimated to be 5 years. The discount rate 
used was 3% per year. Furthermore, to identify what type of research would be of interest (e.g., 
short-term or long-term outcomes), we assessed the EVPI for particular parameters, the expected 
value of partial perfect information (EVPPI). The EVPPI was defined as the difference between the 
expected value of the decision based on existing information and the expected value of the de-
cision based on perfect information on particular parameters (38-41). Analyses were performed 
using TreeAge Pro 2006 (Boston, MA).
RESULTS
Base-case analysis
Quality-adjusted life expectancy was 0.57 QALY higher for endovascular repair than for open 
surgery (5.42 versus 4.85 QALY). Lifetime costs were lower for endovascular repair than for open 
surgery ($ 49,344 versus $ 50,765). Using base-case estimates, endovascular repair yielded more 
QALYs gained and cost less than open surgery (i.e., endovascular repair dominated open surgery) 
(Table 3).
Table 3: Costs and clinical effects for endovascular repair versus open surgery in patients with 
ruptured AAA
QALE = quality adjusted life expectancy, NHB = net health benefits, QALY = quality adjusted life years
* Discounted at 3% per year.
† Endovascular repair dominated open surgery. 
Total lifetime costs (U.S dollars)* QALE (years)* NHB (QALY)
Endovascular repair† 49,344 5.42 4.76
Open surgery 50,765 4.85 4.17
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Sensitivity analysis
The influence of varying 30-day mortality rates for both procedures was evaluated by substitut-
ing a wide range of values for these parameters (Table 1 and 2). If the procedure related com-
plication rate after endovascular repair was < 0.22, endovascular repair remained cost-effective 
compared with open surgery (Table 4).
If 30-day mortality after endovascular repair was ≤ 0.29, endovascular repair was superior to 
open surgery. If 30-day mortality after endovascular repair was ≥ 0.30 and ≤ 0.31, endovascular 
repair was cost-effective compared with open surgery. If 30-day mortality after endovascular re-
pair was ≥ 0.32, open surgery was cost-effective compared with endovascular repair. The model 
was insensitive to any other substitution of parameters given a WTP of $ 75,000 per QALY. 
Value of information analysis
The EVPI was $ 5,836 per patient and the population EVPI was approximately $ 5 million for a 
WTP of $ 75,000 per QALY. This means that if the societal WTP equals $ 75,000 per QALY, the value 
of perfect information concerning the choice of treatment with endovascular repair versus open 
surgery in patients with ruptured AAA, is estimated to be $ 5 million for the Dutch population. 
Using a WTP of $ 120,000 per QALY, the population EVPI was approximately $ 4 million (Figure 
2).  
The EVPPI for short-term clinical risks (i.e., 30-day mortality and procedure-related complications) 
was $ 484,032 (Figure 3). 
Table 4: Threshold values for which endovascular repair was cost-effective compared with open 
surgery in patients with ruptured AAA (incremental cost effectiveness ratio for endovascular 
repair versus open surgery, willingness to pay (WTP) was $75,000 per QALY). 
Parameter EVR dominant ICER < $75,000 per QALY ICER > $75,000 per QALY OSR dominant
Short-term (30-day) procedure related complications EVR ≤ 0.12 ≥ 0.13 and ≤ 0.22 ≥ 0.23 and ≤ 0.27 ≥ 0.28
Short-term (30-day) procedure related complications OSR ≥ 0.14 ≤ 0.13 - -
Short-term (30-day) mortality EVR ≤ 0.29 ≥ 0.30 and ≤ 0.31* - ≥ 0.32†
Short-term (30-day) mortality OSR ≤ 0.40 ≥ 0.41 - -
Costs initial procedure EVR ≤ $45,000 > $45,000 - -
Costs initial procedure OSR > $56,000 ≤ $56,000 - -
EVR = endovascular repair, ICER = incremental cost effectiveness ratio, QALY = quality-adjusted life year, OSR = open surgery
* Open surgery yielded more QALYs and cost more than endovascular repair; endovascular repair was cost-effective given a WTP of $75,000 
per QALY. 
† Open surgery yielded more QALYs and cost more than endovascular repair; open surgery was cost-effective given a WTP of $75,000 per 
QALY. 
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Figure 2: Population expected value of perfect information (EVPI) for the decision between 
endovascular repair and open surgery in patients with a ruptured abdominal aortic aneurysm for 
the Dutch population.
Figure 3: Expected value of partial perfect information (EVPPI) for different types of research in 
the Dutch population.
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The EVPPI for short-term costs (i.e., costs of the initial procedure and procedure-related com-
plications) was $ 2,073,618. The EVPPI for long-term clinical risks (i.e., long-term mortality and 
reinterventions rates) was practically $ 0. The EVPPI for long-term costs (i.e., costs of procedure-
related complications and reinterventions) was also practically $ 0.
DISCUSSION
In this study, we evaluated whether, from a health policy perspective, current available evidence 
justifies today’s policy to treat patients with ruptured AAA with endovascular repair if anatomi-
cally suitable. Treatment with endovascular repair was associated with an increase in QALYs com-
pared with open surgery and a decrease in lifetime costs. In addition, we investigated whether 
additional information should be obtained in order to make better decisions in the future for 
patients with ruptured AAA. Our results suggest that it is justified to initiate further research in 
this area. Furthermore, we concluded that future research should concentrate on short-term (i.e., 
30-day) costs and clinical effectiveness.
On the basis of the parameters used in our model, endovascular repair had higher QALYs and 
lower costs than open surgery. Sensitivity analysis showed that our results were sensitive to 
short-term (i.e., 30-day) complications and mortality after endovascular repair and open surgery 
for the initial ruptured AAA repair, given a WTP of $75,000 per QALY. It should be noted, however, 
that the ability of the operator to perform endovascular repair or open surgery may have an 
impact on the short-term complication and mortality rates and therefore may affect the results 
of our model. In addition, our results were sensitive to costs of the initial endovascular repair or 
open surgery. This indicates that costs of the endografts may affect the results of our model.
The population EVPI of about $5 million indicates that more research is justified. For the USA 
with a much larger population than the Netherlands, the population EVPI would be even higher. 
The population EVPPI indicated that the most relevant information in future research could be 
obtained from research that evaluates short-term (i.e., 30-day) costs and clinical effectiveness. 
The recommended study design for future research is a randomized controlled trial comparing 
endovascular repair with open surgery in patients with ruptured AAA. It should be noted that in 
practice, surgeons tend to apply more lenient criteria for endovascular repair in case of severe 
comorbidity in order to avoid open surgery. This practice should be considered when designing 
randomized controlled trials in patients with ruptured AAA since it may affect generalizability 
of these studies. We found that the additional value of research on long-term costs and clinical 
effectiveness would be relatively small. It should be noted, however, that in our model we based 
the probability to get long-term complications after endovascular repair for ruptured AAA on 
data from patients treated for asymptomatic AAA; therefore the uncertainty for long-term re-
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search was small. This assumption, however, seems to be justified as suggested by Oranen et al. 
(21). In addition, recent literature suggests that current developments in endografts might result 
in better performance and better outcome and that the indication for secondary interventions 
after endovascular repair is changing (42-44).
Several studies compared endovascular repair with open surgery in patients with asymptomatic 
AAAs. In patients treated electively for AAA, endovascular repair was associated with more com-
plications and reinterventions during follow-up compared with open surgery (4, 45). Therefore, 
after 4 years of follow-up, endovascular repair was not cost-effective compared with open sur-
gery in patients electively treated for AAA (4). In our study, the higher costs during follow-up 
after endovascular repair were compensated by lower costs of the initial procedure for endovas-
cular repair compared with open surgery.
Our study had several limitations. The parameters in our model were derived from non- 
randomized observational studies. Therefore, our results may be subject to selection bias. In ad-
dition, several assumptions were made. For example, we assumed that follow-up after endovas-
cular repair for ruptured AAA was similar to follow-up after endovascular repair for elective AAA. 
This may have led to an underestimation of the aneurysm-related complications during follow-up 
for endovascular repair, and therefore an underestimation of the lifetime costs for endovascular 
repair. Furthermore, we assumed a maximum number of procedures performed after failure of 
the initial procedure. In performing sensitivity analyses, however, we investigated the influence 
of these assumptions on the base-case outcomes and found that the model was insensitive to 
the annual aneurysm-related complication rate for both procedures. In addition, in the VOI the 
number of patients that is expected to benefit from additional research was a highly influential 
parameter in the population EVPI. It is not clear whether country-specific or the worldwide popu-
lation should be used as the population that may benefit from further research. Furthermore, 
the lifetime of a technology is another highly influential, uncertain parameter in the VOI. Finally, 
the population EVPI depends on the WTP. To be on the conservative side we used the country- 
specific population, a fairly short lifetime of the technology, and calculated the population 
EVPI for varying WTP which demonstrated a high expected benefit from performing further re-
search. 
More research seems to be justified based on our results. Our VOI analysis suggested that infor-
mation on short-term costs and clinical effectiveness is a key feature in future research. Therefore, 
the authors recommend that, as mentioned above, besides clinical effectiveness, costs will be 
subject of investigation in all research that will be performed in patients with ruptured AAA. 
In conclusion, our results, which were based on the best available data, suggest that endovascu-
lar repair is more effective and costs less compared with open surgery in patients with ruptured 
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AAA. Therefore, current available evidence justifies today’s policy to treat patients with ruptured 
AAA with endovascular repair if anatomically suitable. In addition, further research is justified 
and should concentrate on short-term costs and clinical effectiveness of endovascular repair 
versus open surgery in patients with ruptured AAA. 
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GENERAL DISCUSSION
The aim of this thesis was to determine the optimal treatment for patients with ruptured 
abdominal aortic aneurysm (AAA) using a decision-analytic approach. From both a medical and 
an economic perspective, we evaluated whether these patients should be treated with endovas-
cular repair or open surgery. This thesis describes the findings from the literature in a systematic 
way. Furthermore, the clinical effects and a prediction rule that predicts 30-day mortality in pa-
tients with ruptured AAA after endovascular repair or open surgery were presented. In addition, 
we assessed costs for both treatment options. Also, costs and clinical effects were evaluated in a 
decision analytic model. In this general discussion, the main findings and methodological issues 
are discussed. Finally, implications for future research are considered.
Main findings
In the western world, the population is aging. People over 65 years are the fastest growing age 
group in the coming decades. Therefore, it is not surprising that several studies have indicated an 
increase in abdominal aortic aneurysms (AAAs) and subsequently, ruptured AAAs (1-4).    
Ruptured AAA is a life threatening condition that requires immediate intervention in order to 
avoid death. Mortality in patients with a ruptured AAA treated with open surgery remains high, 
in spite of the exponential growth in technological developments in medicine (5). Since 1994, 
endovascular aneurysm repair in patients with a ruptured AAA has proven to be feasible and has 
become an important and increasingly performed alternative to open surgery in patients with 
ruptured AAA (6-18). 
Since the introduction of endovascular repair for patients with ruptured AAA, the treatment 
policy for these patients changed. Due to the minimal invasive nature of endovascular repair, 
most physicians assume that endovascular repair is the best treatment for these patients. In 
sufficiently equipped hospitals, patients who are hemodynamically stable receive a CT-scan or 
angiography prior to the procedure to assess anatomic eligibility for endovascular repair. If pa-
tients are anatomically suitable they are treated with this procedure, if not, they are treated with 
open surgery. Those who are hemodynamically too unstable are immediately transported to the 
operating room for open surgery (19).
We systematically evaluated published studies comparing endovascular repair with open sur-
gery in patients with ruptured AAA and adjusted for differences in inclusion criteria among the 
studies. We found that 30-day mortality after adjustment for patients’ hemodynamic condition 
upon presentation was not statistically significant for endovascular repair compared with open 
surgery in patients with ruptured AAA.
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Furthermore, in a clinical study we found that 30-day mortality and morbidity were similar for en-
dovascular repair and open surgery in patients with ruptured AAA; this similarity was sustained 
after one-year follow-up (20). In the absence of randomization, we focused our comparison on 
hemodynamically stable patients to make the treatment groups more homogeneous and the 
comparison as valid as possible.
To identify patients that may benefit more from endovascular repair than others, we stratified ac-
cording to risk for cardiac complications after the procedure. Our results suggested that patients 
with lower risk for cardiac complications had a better chance to survive and had less morbidity 
after open surgery than after endovascular repair. In contrast, patients with higher risk for cardiac 
complications were better off with endovascular repair than with open surgery.  
The Glasgow Aneurysm Score (GAS) is a prediction rule recommended to predict in-hospital 
mortality after open surgery for patients with ruptured and unruptured AAA (21). In our study, 
the GAS showed limited discriminative abilities in patients with ruptured AAA treated with en-
dovascular repair or open surgery. The limited discriminative ability of the GAS may be due to 
the introduction of endovascular repair in patients with ruptured AAA. When the GAS was devel-
oped, only open surgery was applied to treat ruptured AAAs. In addition, the limited discrimina-
tive ability of the GAS suggests that factors not involved in the GAS influenced mortality after 
repair for ruptured AAA. We modified the GAS into a prediction rule that predicts 30-day mortal-
ity after endovascular repair or open surgery by adding patients’ hemodynamic stability prior 
to the procedure and the type of procedure performed to the GAS variables. We showed that, 
considering the included risk factors, 30-day mortality was always lower if patients with ruptured 
AAA were treated with endovascular repair as opposed to open surgery, although these results 
were not statistically different. 
In-hospital costs for endovascular repair seemed to be lower than for open surgery (22). The 
most important cause for this difference was the costs of the ICU. Patients who underwent en-
dovascular repair were admitted to the ICU less often than patients treated with open surgery. 
In addition, the length of stay in the ICU and in the hospital also played an important role, which 
was shorter for patients treated with endovascular repair than for patients who underwent open 
surgery. Costs of the procedures itself did not differ. However, the component costs were quite 
different between the procedures. Costs of the operating room, anesthesiology and personnel 
were higher in patients who underwent open surgery, caused by the longer procedure time in 
these patients. The higher costs of materials in patients who underwent endovascular repair 
were mainly caused by the use of expensive endografts. The high costs of blood products in 
patients who underwent open surgery, was caused by the large amount of blood loss in these 
patients. These differences cancelled out, leading to similar total costs of the procedures. 
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Furthermore, costs of one-year follow-up were higher for endovascular repair compared with 
open surgery. This was to be expected since regular CT-scans were performed to identify possi-
ble endoleaks, graft migration or other complications related to the endovascular repair (23-25). 
In addition, patients who undergo endovascular repair probably will have more re-interventions 
in the long run due to these graft related failures (26). Overall, however, total costs, including in-
hospital costs and costs of one-year follow-up, were lower for endovascular repair than for open 
surgery.
 
Using results from the above studies, we evaluated whether, from a health policy perspective, 
current available evidence justifies today’s policy to treat patients with ruptured AAA with 
endovascular repair if anatomically suitable, using a decision analytic model. Treatment with en-
dovascular repair was associated with an increase in QALYs compared with open surgery and a 
decrease in lifetime costs. In addition, we investigated whether additional information should 
be obtained in order to make better decisions in the future for patients with ruptured AAA. Our 
results suggest that it is justified to initiate further research in this area. Furthermore, we con-
cluded that future research should concentrate on short-term (i.e., 30-day) costs and clinical 
effectiveness.
Overall, from the patients’ perspective, we were able to demonstrate lower short-term mortality 
after endovascular repair compared with after open surgery, although this difference was not 
statistically different. It is likely that some patients will benefit from endovascular repair whereas 
others may not. On one hand, patients with severe comorbidity are likely to benefit from endo-
vascular repair, as suggested in chapter 3. On the other hand, patients with an AAA anatomy 
unsuitable for endovascular repair are unlikely to benefit from this procedure. Therefore, proper 
selection is needed in order to give patients the best available treatment.
Furthermore, from a health policy perspective, it is likely that endovascular repair is cost- 
effective compared with open surgery. Therefore, current available evidence justifies today’s 
policy to treat patients with ruptured AAA with endovascular repair if anatomically suitable.
Methodological considerations
To determine effectiveness of treatments, a randomized controlled clinical trial is the recom-
mended study design. In this thesis, however, only observational research was included. With 
this approach, several problems exist and therefore caution must be exercised when interpreting 
the results of this thesis. 
In the systematic review, no randomized controlled clinical trials were included and only obser-
vational studies were available. Observational studies are prone to selection bias. The effect of 
this bias is likely to be in favor of endovascular repair since all patients treated with this proce-
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dure were in a hemodynamically stable condition upon presentation to the hospital as opposed 
to those who were treated with open surgery. In addition, as with many reviews, definitions and 
protocols varied across the studies, sometimes definitions or data were not reported. Further-
more, the systematic review may have been affected by publication bias (i.e., the greater likeli-
hood of publication of positive results or results based on large sample sizes). Small studies with 
higher mortality rates for endovascular repair than for open surgery seemed to be underrepre-
sented, which may have favored endovascular repair. In addition, uncertainty remains concern-
ing the long-term effectiveness of endovascular repair for patients with a ruptured AAA. 
In the clinical analysis, the patients were not randomly assigned to endovascular repair and open 
surgery but selection was based on patients’ hemodynamic condition and anatomic suitability 
for endovascular repair. Therefore, selection bias may be present. In addition, the sample sizes of 
both treatment groups were small and follow-up was limited to one year. Consequently, long-
term effectiveness of endovascular repair versus open surgery in patients with ruptured AAA 
remains unclear.
Prediction rules can be used to predict mortality after a procedure. Our aim was to validate the 
GAS and to modify this into a prediction rule that can be used for both endovascular repair and 
open surgery in patients with ruptured AAA. The definitions of risk factors were slightly different 
from the original GAS. Furthermore, the data for the prediction rule was not based on a ran-
domized controlled trial; therefore selection bias may have affected our results. In addition, the 
treatment protocols between the participating hospitals were slightly different. The criteria for 
patients being hemodynamically (un)stable differed across the hospitals. In addition, the types 
of endografts on stock were not similar for all hospitals. As a result, different anatomic criteria 
were applied across the participating hospitals. Observational studies, however, may be a better 
representation of daily clinical practice than randomized controlled trials .
In the cost analysis, the main problem was that the data were not based on a randomized con-
trolled trial; therefore selection bias may be present. Also the sample size was relatively small and 
the follow-up was limited to one year. The small sample size made it hard to distinguish between 
statistically significant and insignificant findings. Another limitation of this study was the pos-
sible limited generalizability of the results to other countries as different accounting systems are 
used across countries.
Decision-analytic models can evaluate cost-effectiveness (30). In these models, however, as-
sumptions have to be made since reality is complex. Another limitation of such models is that 
the input parameters come from multiple sources. In the model we developed, all data of the 
above studies was used. These data, however, were derived from non-randomized observational 
studies making the results subject to selection bias. An advantage of these models is that strat-
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egies can be compared with lifetime follow-up. In the value-of-information (VOI) analysis, the 
number of patients that is expected to benefit from additional research was a highly influential 
parameter in the population EVPI. It is not clear whether country-specific, continent-specific, or 
the worldwide population should be used as the annual population to benefit. Furthermore, the 
lifetime of a technology and the societal willingness-to-pay were highly influential, uncertain 
parameters in the VOI. 
As far as we know, one randomized controlled trial is ongoing (31) but it may take years before 
results are available. As endovascular repair is increasingly performed, data of solid research are 
needed at this time. Several biases are present, however, decisions have to be made and there-
fore, presenting the available evidence in a structured way contributes to the decision-making 
process in patients with ruptured AAA.
Future directions
Based on results from our value-of-information analysis, more research on endovascular repair 
versus open surgery in patients with ruptured AAA seems justified. It should be noted, however, 
that this conclusion is only valid if effects and costs of both treatment options remain unchanged. 
In addition, in the value of information calculations, the improvement of treatments, such as bet-
ter endografts, was not taken into account.
Our results suggested that information on short-term costs and clinical effectiveness is a key 
feature in future research. Therefore, we recommend that, besides clinical effectiveness, costs 
will be subject of investigation in all research that will be performed in patients with ruptured 
AAA. Furthermore, more data on follow-up than currently available seems to give no expected 
improvement on the decision whether patients should be treated with endovascular repair or 
open surgery. 
In addition, more research focusing on selection criteria and survival chances needs to be per-
formed. A predictive tool may be used to identify patients who may benefit from endovascular 
repair and those who are unlikely to benefit from this procedure. Furthermore, future studies 
should investigate which patients should go immediately to the operating room for open sur-
gery and which patients should undergo imaging prior to the therapeutic procedure to deter-
mine anatomic eligibility for endovascular repair. Similar to hemodynamically stable patients, 
hemodynamically unstable patients might better undergo endovascular repair than open 
surgery if the anatomy is suitable. Therefore, it remains to be clarified whether hemodynami-
cally unstable patients should undergo imaging prior to the procedure, although most patients 
appear to be sufficiently stable to do so (32). In addition, since patient populations may change 
overtime, the development of a prediction tool is an ongoing process; therefore we encourage 
further validation and adjustment of our new prediction rule. 
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Furthermore, we recommend ongoing prospective observational research in patients with rup-
tured AAA. Prospective observational studies reflect daily practice and changes in treatment 
policy overtime (28, 29). This is of particular interest in this group of patients, since new types 
of endografts, requiring more lenient anatomic criteria, are becoming rapidly available. Obser-
vational studies are needed alongside randomized clinical trials since they provide additional 
information about clinical practice . Whereas randomized trials assess efficacy under controlled 
conditions in highly selected patients, observational studies assess effectiveness as observed in 
daily clinical practice. 
The recommended study design for future research is a randomized controlled trial comparing 
endovascular repair with open surgery in patients with ruptured AAA. It should be noted that in 
practice, surgeons tend to apply more lenient criteria for endovascular repair in case of severe 
comorbidity in order to avoid open surgery. This practice should be considered when designing 
randomized controlled trials in patients with ruptured AAA since it may affect generalizability 
of these studies. Whatever study will be undertaken, generalizability and a limited time horizon 
are always limitations that have to be dealt with. Nevertheless, especially in a field where rapid 
technology improvements are expected to be made, it should be questioned whether a random-
ized trial is the ultimate way of performing research since generalizability of that research will be 
limited.
Whereas this thesis rather focused on the curative part of the ruptured AAAs, it is always better to 
prevent than to cure. Therefore, future research regarding ruptured AAAs should take prevention 
of AAA into account. A recently published study showed that angiotensin converting enzyme 
(ACE) inhibitors may be related to a lower chance of rupture of the AAA (33). This research high-
lights the need for further investigation in prevention of rupture of the AAA. Furthermore, prob-
ably the most gain in survival in patients with ruptured AAA can be obtained by the introduction 
of a screening program in patients at risk to develop an AAA (34). Nowadays, families in which 
AAAs were previously diagnosed undergo abdominal ultrasounds regularly to detect a possible 
AAA at an early stage. In addition, all males over the age of 65 are likely to benefit from screening 
for AAA (35). 
In summary, the results of this thesis demonstrate that endovascular repair and open surgery are 
feasible in patients with ruptured AAA. With the current knowledge, it seems justified to treat all 
anatomically eligible patients with a ruptured AAA with endovascular repair. Further research 
in this area is justified and should concentrate on short-term (i.e., 30-day) clinical effectiveness 
and costs. In addition, the development of a prediction tool to identify patients who may benefit 
from endovascular repair and those who are unlikely to benefit from this procedure is an ongo-
ing process; therefore, we encourage further validation and updating of our prediction rule.
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SUMMARY
This thesis describes studies on the evaluation of endovascular repair versus open surgery in 
patients with ruptured abdominal aortic aneurysm (AAA). In chapter 1, the rationale for this 
research is presented. Since in the western world, the population is aging, it is expected that 
the incidence of abdominal aortic aneurysms will increase and consequently, ruptured AAAs. 
Ruptured AAA is a life threatening condition that requires immediate intervention. The condition 
can be treated with endovascular repair or open surgery. Therefore, the aim of this thesis was to 
investigate whether endovascular repair or open surgery would be the preferred treatment in 
this group of patients from a decision-analytic approach, taking clinical effectiveness as well as 
costs into account.
To enable comparison of the results of endovascular repair with open surgery in patients with 
a ruptured AAA from the literature, it is important to systemically evaluate the published stud-
ies and to adjust for differences in inclusion criteria among the studies. In chapter 2, we per-
formed a systematic review of studies that compared endovascular repair with open surgery in 
the treatment of patients with a ruptured AAA. We found that, after adjustment for patients’ he-
modynamic condition upon presentation, a benefit in 30-day mortality for endovascular repair 
compared with open surgery for patients with a ruptured AAA was observed but was not statisti-
cally significant. 
In chapter 3, we compared the clinical outcomes of treatment after endovascular repair and 
open surgery in patients with ruptured infrarenal AAAs including one-year follow-up. It turned 
out that in our study with a highly selective population, mortality and morbidity might be simi-
lar for patients with a ruptured infrarenal AAA treated with endovascular repair compared with 
open surgery, even after one-year follow-up. In addition to the aneurysm anatomy, other criteria 
may be needed for endovascular repair to improve clinical outcomes. 
The Glasgow Aneurysm Score (GAS) is a prediction rule to predict in-hospital mortality after open 
surgery for patients with ruptured and unruptured AAA. The GAS, however, was developed in 
patients treated with open surgery only, whereas nowadays, endovascular repair is the preferred 
treatment for repair of ruptured AAA in many European hospitals. In chapter 4, the GAS was 
validated in patients with ruptured AAA treated with endovascular repair or open surgery. In ad-
dition, our aim was to modify the GAS into an updated prediction rule that predicts 30-day mor-
tality after endovascular repair or open surgery. We found that the GAS showed limited discrimi-
native ability in our patient population. In addition, we showed that, considering the included 
risk factors, 30-day mortality was always lower if patients with ruptured AAA were treated with 
endovascular repair instead of with open surgery.
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To evaluate the incurred costs of both endovascular repair and open surgery, it is important 
to calculate both in-hospital costs and costs during follow-up after the procedure. Chapter 5 
describes the retrospectively assessment of in-hospital costs and costs of one-year follow-up 
of endovascular repair and open surgery in patients with an acute infrarenal AAA, using the re-
source utilization approach. We found that total costs including in-hospital costs and one-year 
follow-up in patients with acute infrarenal AAA were lower for endovascular repair than for open 
surgery.
From a health policy perspective, it should be questioned whether current available evidence 
justifies today’s policy to treat patients with ruptured AAA with endovascular repair if ana-
tomically suitable. In addition, it is of interest whether additional information is required to 
inform the decision making process for patients with ruptured AAA in the future. Therefore, in 
chapter 6, we evaluated the cost-effectiveness of endovascular repair compared with open 
surgery in patients with ruptured AAA and investigated whether performing future research to 
obtain additional information is justified. We concluded that endovascular repair was more ef-
fective and less costly compared with open surgery in patients with ruptured AAA. Therefore, 
current available evidence does justify today’s policy to treat patients with ruptured AAA with 
endovascular repair if anatomically suitable. In addition, further research is justified and should 
concentrate on short-term costs and clinical effectiveness of endovascular repair versus open 
surgery in patients with ruptured AAA. 
In chapter 7 the main findings were summarized of the preceding chapters and placed in a broad-
er context. In addition, methodological considerations and future research were discussed.
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Dit proefschrift beschrijft studies over de evaluatie van de endovasculaire behandeling versus 
open chirurgie in patiënten met een geruptureerd aneurysma van de abdominale aorta (AAA). 
In hoofdstuk 1 wordt de achtergrond van dit onderzoek beschreven. Doordat in de Westerse 
wereld de bevolking in een hoog tempo vergrijst, is de verwachting dat de incidentie van AAA’s 
en daarmee van geruptureerde AAA’s zal toenemen. Een geruptureerd AAA is een levensbedrei-
gende aandoening die onmiddelijk ingrijpen noodzakelijk maakt. De patiënt kan worden be-
handeld met een endovasculaire behandeling of met open chirurgie. Daarom is de doelstelling 
van dit proefschrift te onderzoeken, vanuit een medisch besliskundige benadering waarin zowel 
klinische effecten als kosten in beschouwing worden genomen, of endovasculaire behandeling 
danwel open chirurgie de voorkeur verdient in patiënten met een geruptureerd AAA. 
Om de resultaten van de endovasculaire behandeling en open chirurgie in patiënten met een 
geruptureerd AAA uit de literatuur met elkaar te kunnen vergelijken, is het belangrijk om de ge-
publiceerde studies systematisch te evalueren en te corrigeren voor verschillen in inclusiecriteria 
tussen de verschillende studies. In hoofdstuk 2 hebben we de resultaten van een systematisch 
literatuur onderzoek gepresenteerd van studies die de endovasculaire behandeling en de open 
chirurgische behandeling in patiënten met een geruptureerd AAA met elkaar vergeleken. We 
vonden dat, na correctie voor de conditie van de patiënt op het moment dat hij/zij zich presen-
teerde in het ziekenhuis, er spake was van een voordeel in 30-dagen mortaliteit. Dit verschil was 
echter niet statistisch significant. 
In hoofdstuk 3 vergeleken we de klinische uitkomsten na endovasculaire behandeling en open 
chirurgie in patiënten met een geruptureerd infrarenaal AAA, inclusief 1 jaar follow-up. Uit onze 
studie, met een sterk geselecteerde populatie, bleek dat mortaliteit en morbiditeit wellicht gelijk 
zijn voor patiënten met een geruptureerd AAA die endovasculair behandeld zijn in vergelijking 
met open chirurgie, ook na 1 jaar follow-up. Bovendien bleek dat, naast de anatomie van het 
aneurysma, waarschijnlijk andere criteria nodig zijn om de klinische uitkomsten van de endovas-
culaire behandeling verder te verbeteren. 
De Glasgow Aneurysm Score (GAS) is een predictieregel die de ziekenhuis mortaliteit na open 
chirurgie voor patiënten met een geruptureerd en een niet-geruptureerd AAA voorspelt. Ech-
ter, de GAS is ontwikkeld in patiënten die allen met open chirurgie zijn behandeld, terwijl te-
genwoordig de endovasculaire behandeling de behandeling van voorkeur is in veel Europese 
ziekenhuizen voor patiënten met een geruptureerd AAA. In hoofdstuk 4 is de GAS gevalideerd 
in patiënten met een geruptureerd AAA die behandeld zijn met endovasculaire behandeling of 
open chirurgie. Bovendien was onze doelstelling om de GAS te modificeren in een bijgewerkte 
predictieregel die de 30-dagen mortaliteit na endovasculaire behandeling of open chirurgie 
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voorspelt. We vonden dat de GAS beperkte discriminerende mogelijkheden had in onze pa-
tiënten populatie. Bovendien toonden we aan dat, gegeven de geïncludeerde risicofactoren, de 
30-dagen mortaliteit lager was als patiënten met een geruptureerd AAA endovasculair werden 
behandeld in plaats van met open chirurgie. 
Om alle kosten van de endovasculaire behandeling en open chirurgie te evalueren is het belang-
rijk om zowel de ziekenhuiskosten als de kosten tijdens follow-up na de procedure te berekenen. 
Hoofdstuk 5 beschrijft de retrospectieve bepaling van de ziekenhuiskosten en de kosten van 1 
jaar follow-up van de endovasculaire behandeling en open chirurgie in patiënten met een acuut 
infrarenal AAA met behulp van de ‘resource utilization’ aanpak. We vonden dat de totale kosten, 
inclusief de ziekenhuiskosten en de kosten van 1 jaar follow-up, lager waren voor de endovascu-
laire behandeling dan voor open chirurgie.
Vanuit een beleidsperspectief in de gezondheidszorg dient men zich af te vragen of het beschik-
bare bewijs het hedendaags beleid rechtvaardigt om patiënten met een geruptureerd AAA en-
dovasculair te behandelen als ze anatomisch geschikt zijn voor deze behandeling. Bovendien 
is het interessant te weten of aanvullende informatie is vereist om het beslissingsproces voor 
patiënten met een geruptureerd AAA in de toekomst te optimaliseren. Daarom evalueerden we 
in hoofdstuk 6 de kosten-effectiviteit van de endovasculaire behandeling in vergelijking met 
open chirurgie in patiënten met een geruptureerd AAA en onderzochten we of het uitvoeren 
van verder onderzoek om extra informatie te verkrijgen is gerechtvaardigd. We concludeerden 
dat de endovasculaire behandeling effectiever en goedkoper was dan open chirurgie. Daarom 
rechtvaardigt het beschikbare bewijs het hedendaags beleid om patiënten endovasculair te be-
handelen als ze anatomisch geschikt zijn voor deze behandeling. Bovendien is verder onderzoek 
gerechtvaardigd. Dit dient zich te concentreren op de korte termijn (30-dagen) klinische effecten 
en kosten van de endovasculaire behandeling versus open chirurgie in patiënten met een gerup-
tureerd AAA.
In hoofdstuk 7 zijn de belangrijkste bevindingen van de voorgaande hoofdstukken samengevat 
en in een bredere context geplaatst. Bovendien worden de methodologische overwegingen en 
de mogelijkheden van vervolgonderzoek besproken.
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